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SUMMARY (English) 
A senescent cell experiences proteotoxic stress in consequence to senescence-
associated secretory phenotype (SASP). SASP factors involve increased production 
of cytokines and chemokines, which overload and disrupt protein homeostasis. This 
induces endoplasmic reticulum (ER) stress, unfolded protein response (UPR) as well 
as elevated autophagic-lysosomal burden in senescent cells, further promoting the 
formation of misfolded proteins.  
In this thesis we found, in Eμ-myc transgenic mice lymphomas, therapy-induced 
senescence (TIS) by Adriamycin or Cyclophosphamide treatment leads to an up 
regulation of genes involved in Alzheimer’s disease (AD). However, this is true only 
when TIS correlates with SASP, leading to proteotoxicity. On the other hand, we 
demonstrate that transgenic AD inflicted mice also present with features of 
senescence. Mutations of genes such as amyloid precursor protein (APP) and 
presenilin1 (PSEN1), not only engender AD, but also augment senescence. In 
APPPS1+/- transgenic mice, the senescent cells co-occur with amyloid β (Aβ) 
plaques. Likewise, in neuroblastoma cell line SH-SY5Y, APP overexpression results 
in upregulation of senescence markers, including markers for ER stress and 
autophagic-lysosomal burden. These observations imply that there is a crosstalk 
between senescence and AD. 
We demonstrate proteotoxicity as a common denominator between the two 
pathologies. However, we found that APP and PSEN1 are not regulators of TIS. 
APP contributes to proteotoxic stress associated with TIS as knocking down of APP 
leads to a reduction of ER stress. Inhibiting Aβ formation by targeting the processing 
of APP using Semagacestat- a gamma-secretase inhibitor, selectively targets 
senescent cells resulting in cell death. This indicates its senolytic potential. However, 
Semagacestat has no impact on the expression of ER stress markers. This 
suggested that in Eμ-myc lymphomas, APP contributes to ER stress in an Aβ-
independent fashion, unlike in AD, where Aβ is considered central to its 
pathophysiology.  
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SUMMARY (German) 
Eine seneszente Zelle erfährt proteotoxischen Stress durch einen Prozess, der als 
“Seneszenz-assoziierter sekretorischer Phänotyp (SASP)” bezeichnet wird. SASP 
Faktoren involvieren vermehrte Produktion von Cytokinen und Chemokinen, die die 
Proteinhomöostase stören. Das führt zu Stress im Endoplasmatischen Retikulum 
(ER), Unfolded Protein Response (UPR) sowie erhöhter Autophagie in seneszenten 
Zellen. In dieser Arbeit zeigen wir, dass Therapie-induzierte Seneszenz (TIS), 
ausgelöst durch Adriamycin (ADR) oder Cyclophosphamid (CTX), zu einer erhöhten 
Expression von Alzheimer-assoziierten Genen führt. Das ist allerdings nur der Fall, 
wenn TIS mit SASP und Proteotoxizität korreliert. Außerdem zeigen wir, dass 
transgene Mäuse mit Alzheimer ebenso Eigenschaften von Seneszenz aufweisen. 
Mutationen in Genen wie Amyloid-Precursor-Protein (APP) und Presenilin 1 
(PSEN1) erzeugen nicht nur Alzheimer, sondern verstärken auch Seneszenz. In 
APPPS1+/- transgenen Mäusen treten seneszente Zellen zusammen mit Amyloid β 
(Aβ) Plaques auf. Gleichfalls führt die Überexpression von APP in der Neuroblastom 
Zelllinie SH-SY5Y zu einer Erhöhung von Seneszenz-Markern, einschließlich ER 
Stress und Autophagie-assoziierten Lysosomen. Diese Beobachtungen implizieren 
einen Zusammenhang zwischen Seneszenz und Alzheimer. 
Wir präsentieren Proteotoxizität als gemeinsamen Nenner dieser beiden 
Pathologien. Allerdings kommen wir zu dem Ergebnis, dass APP und PSEN1 keine 
Regulatoren von TIS sind. APP trägt zur TIS-assoziierten Proteotoxizität bei, da ein 
knock-down von APP zu einer Reduzierung des ER Stress führt. Außerdem, können 
seneszente Zellen mittels Blockierung der APP Spaltung und somit Bildung von Aβ 
Plaques durch den Gamma-Sekretase Inhibitor Semagacestat, selektiv getötet 
werden. Das deutet auf ein senolytisches Potential hin. Allerdings hat Semagacestat 
keinen Einfluss auf die Expression von ER Stress Marker. Dies suggeriert, dass APP 
in Eμ-myc Lymphomen Aβ-unabhängig zu ER Stress beiträgt, während diese in 
Alzheimer eine zentrale Rolle in der Phathophysiologie spielen. 
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INTRODUCTION 
 1 Cellular senescence  
Cellular senescence is a phenomenon that limits the propagation of a normal cell 
and leads it to a state of growth arrest1. Unlike quiescence, this cell cycle arrest is 
stable as the cells fail to re-enter the mitotic cell cycle, even when the stress 
inducing senescence is removed2. Senescence is an alternative mechanism to 
restrict potentially harmful cells from proliferating. In general, senescence can be 
triggered in a normal cell by various cellular stresses, such as telomere uncapping 
and DNA damage response (DDR). Particularly, cancer cells can enter senescence 
via activation of an oncogene (oncogene-induced senescence/OIS) or radio- and 
chemotherapy that generally induces DDR (therapy-induced senescence/TIS)2–6. 
Other senescence inducing stimuli include reactive oxygen species (ROS), and 
unfolded protein response elements7–9. 
Key features of a senescent cell are G1 phase arrest of the cell cycle, adoption of a 
typical flat and vacuole rich cytoplasmic morphology, while continuing their cellular 
metabolic activities. Senescent cells are synonymous with an enhanced lysosomal 
activity of the β-galactosidase enzyme. This is used as a tool for detection of 
senescent cells, using X-gal as a substrate10. 
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Figure 1: Various modes of senescence induction. These stimuli are usually 
present in the tumor environment. Induction of senescence acts as a protective 
mechanism to prevent the proliferation of cancerous cells. Figure from Collado et al. 
20065. 
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 1.1 Oncogene-Induced Senescence 
OIS acts as a cellular defense mechanism that is initiated upon activation of an 
oncogene. Approximately 50 oncogenes possess the ability to initiate an OIS 
response. Ras was first reported to induce senescence when overexpressed in 
human fibroblasts6,11. Many downstream pathways of Ras are involved in terminal 
cell cycle arrest, for e.g. the MAPK cascade and PI3 kinase/Akt pathway. The Ras 
pathway is involved in the promotion of translocation and activation of FoxO 
transcription factors, depending on the signaling events12. Alternatively, loss of tumor 
suppressors such as PTEN, can also initiate an OIS response13. Therefore, genes 
that initiate uninhibited proliferation could potentially lead to senescence. 
The role of OIS has been established in vivo, where it deters tumor formation at an 
early stage14–17. For instance, Ras driven mouse lung adenoma/adenocarcinoma 
display a presence of cells under cell cycle arrest, mimicking features of cellular 
senescence17. However, inactivation of senescence by genomic deletion of Suv39h1 
in B-cell lymphomas permits these cells to evade the tumor-suppressive potential 
associated with the oncogenic Ras induced senescence16. Malignancy is also 
observed in case of loss of tumor suppressor PTEN, despite the induction of cellular 
senescence. In this scenario, the activated oncogene is unable to induce 
senescence because loss of PTEN leads to inactivation of p53, which in turn 
bypasses senescence18. Thereby suggesting that OIS does not always succeed to 
form a barrier between uncontrolled cell proliferation and tumor formation. 
Apart from oncogenes that induce OIS, such as Ras and Raf, some other 
oncogenes do not have the same response. For instance they induce apoptosis as 
their primary cellular failsafe response, such as via c-Myc6,19–21. 
 1.2 Therapy-Induced Senescence (DNA-Damage Response) 
In cases where cancer cells evade the tumor suppressing OIS, the cells become 
immortal and proliferate in an uncontrolled manner22. While this suggests that 
possibly the senescence machinery is faulty in these cancer cells, these cells remain 
responsive to TIS. This could be because there are various different pathways that 
are involved in senescence regulation23–25. There also remains a probability that 
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cells are required to retain some levels of cell cycle regulators to ensure mitotic cell 
divisions26. Hence, when OIS fails to act as a failsafe mechanism, TIS can be used 
as an alternative method to curb tumor formation and growth. 
Senescence can also be induced by an increase in the intracellular levels of ROS. 
This is true for mortal as well as immortal cells, by causing DNA, lipid or protein 
damage27. For instance, oxidative stress induced by Zn2+ ionophore pyrithione is 
known to induce growth arrest leading to senescence28,29. Moreover, PTEN 
hemizygous cells undergo TIS when treated with PTEN inhibitor VO-OHpic. This 
was induced in cancer cells in mouse models as well as human xenografts13. This 
leads to a conclusion that susceptibility of some cancers to TIS can be targeted via 
some stress-signaling responses. It was also observed that in these cases, TIS 
occurred independent of DDR13. 
 1.3 The Eμ -myc mouse lymphoma model  
The Eμ-myc mouse lymphoma model was derived from a mouse plasmocytoma. 
The transgenic mouse with a rearranged c-myc oncogene was generated30. The Eμ-
myc transgene constitutes an insertion of 361 bp 5' to the c-myc gene on 
chromosome 15, which consists of a 2.3 kb segment of the immunoglobulin heavy 
(H) chain locus from chromosome 12. This insertion includes the lymphoid- specific 
enhancer from the Ig heavy chain locus region and interferes with the normal 
expression of c-myc. The resulting Eμ-myc transgenic mice express the transgene 
predominantly in B-lymphoid cells and engender the development of B cell 
lymphomas which resemble human non-Hodgkin lymphomas31. This model is 
beneficial since the resulting lymphomas can be detected by palpation of the 
peripheral lymph nodes and can hence be subjected to treatment in vivo or ex vivo. 
Lymphoma cells can be cultured for a limited period in vitro, allowing genetic 
modifications (e.g. by retroviral infection) and treatments. When apoptosis is blocked 
by overexpression of bcl2, for example, these cells homogeneously enter 
senescence and serve an excellent model system for TIS32.  
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 1.4 Molecular pathways of senescence 
 
 
Figure 2: p53 and Rb - the key regulators of senescence. Rb is activated by p53 
via p21 as well as other factors. Rb inhibits transcription of E2F target genes, 
thereby activating senescence. Via p21 and p16INK4a are two pathways of Rb 
activation. Phosphorylation of p53 is essential for senescence execution. Players 
such as ATM/ATR and Chk1/Chk2 proteins, p19ARF- product of the INK4a locus 
responsible for impeding mdm2 are all factors contributing to the activation of p53. 
Figure modified from Porath and Weinberg 20054. 
DDR is induced as a result of hindered DNA replication machinery and/or reactive 
oxygen species (ROS)33–36. The DDR induces a kinase dependent activation of the 
tumor suppressor p53, via the ataxia telangiectasia–mutated (ATM) and ataxia 
telangiectasia and Rad3-related (ATR) kinase pathways. The intensity of these 
responses and the specific underlying pathways vary between cell types13. Stable 
activation of p53 protein further activates its targets such as cyclin-dependent kinase 
(CDK) inhibitors p16, p15, p21 and p2723. CDK-cyclin inhibition results in proliferative 
arrest, whereas senescence is induced via the hypo-phosphorylated form of Rb37. 
Activation of p21 via p53 therefore serves as a relevant marker for senescence38,39. 
Both p53 and Rb are necessary for the senescence initiation4. Inactivation of p53 in 
mouse embryonic fibroblasts (MEFs) prevents the cells from undergoing senescence 
as well as allows re-entry into the cell cycle40,41. Therefore, p53 and Retinoblastoma 
(Rb) are key to cell cycle regulation, since they regulate most of the players involved 
in cell cycle progression and play an essential role in senescence.  
Rb is one of the most important regulators of the G1 to S transition of the cell cycle. 
The active form of Rb, bound to the E2F family, leads to the repression of their 
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transcriptional targets42, which in turn induces senescence. E2F transcription factors 
regulate genes that promote entry into the S phase of the cell cycle43. Rb activity is 
regulated via the p53/p21pathway, or via the p16INK4a pathway, or in parallel by 
both4. Hence, a combination of p53 and Rb pathways determines the final level of 
stress experienced by the cell. This decides the ultimate cellular response that is 
activated4. Rb and p16INK4a are essentially the cell cycle players associated with 
maintaining the irreversibility of senescent cells back into the cell cycle6,44–48. 
The p16INK4a protein is a commonly used marker for senescence. Its expression 
could be induced by different stresses as well as by senescence49–51. It indirectly 
regulates the activation of Rb by inhibiting Cyclin D/Cdk4 complex that would 
otherwise phosphorylate and inactivate Rb43,52. Inactivation of Rb releases E2Fs to 
initiate the corresponding transcriptional program. Mouse Eμ-myc transgenic 
lymphomas with Bcl2 overexpression undergo senescence in response to 
chemotherapy in a p16INK4a dependent manner53. 
Furthermore, there are several epigenetic modifications associated with senescence. 
Trimethylation of Lys9 on histone H3 (H3K9me3) modifications and heterochromatin 
protein 1 (HP1) binding, especially at E2F target genes, are universally used to 
indicate the senescent population in cell culture. Rb along with HP1 and histone 
methyltransferases associate themselves with E2F promoters during senescence, 
possibly forming senescence-associated heterochromatic foci (SAHF) and 
establishing senescence42,45. However, SAHFs have limitations serving as a marker 
for senescence since they appear in human but not always in mouse senescent 
cells54–56. 
Since many players are involved in various aspects of senescence, but not all of 
them might be expressed in all cell types. Taken together in combinations, they can 
be used as molecular markers of senescence. 
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 1.5 Senescence-Associated Secretory Phenotype 
Senescence is also associated with secondary features such as Senescence 
Associated Secretory Phenotype (SASP)57. SASP is a complex phenotype, where 
senescent cells increase the expression of secreted proteins, including enzymes 
responsible for the degradation of extracellular matrix as well as NF-κB dependent 
pro-inflammatory cytokines58. It includes pro-inflammatory cytokines such as 
interleukin-6 (IL-6) and interleukin-8 (IL-8), chemokines like monocyte 
chemoattractant proteins (MCPs) and macrophage inflammatory proteins (MIPs), 
immune modulators, growth factors such as transforming growth factor-β (TGFβ) 
and granulocyte-macrophage colony-stimulating factor (GM-CSF), and 
proteases57,59,60. SASP is arguably observed to have contravening roles of 
promoting senescence and in some cases promoting tumorigenesis61–66 (Figure 3). 
These factors could cause inflammation and could be essential for the phagocytotic 
clearance of senescent cells63,67. Hence, SASP can constitute a microenvironment 
that could possibly lead to the removal of senescent cells, through its intrinsic 
paracrine and autocrine activities23. On the other hand, SASP is also noted for its 
ability to trigger senescence, in a paracrine manner, via the ROS and DNA-damage 
pathways 62,68,69. Thus, SASP factors contribute towards many biological processes 
which may or may not be adept to clear harmful cells. 
SASP contributes to the proteotoxic stress associated with senescence, by 
exhausting the capacity of cells to maintain accurate protein synthesis, post-
translational processing, vesicular transport and secretion. Thus, autophagy is also 
induced in these conditions, which could be an effort to cope with this proteotoxic 
stress70.  
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Figure 3: Senescence-associated secretory phenotype (SASP). SASP involves 
secretion of factors contributing to the maintenance of the senescent state and 
growth arrest of senescent cells (the autocrine effect), as well as influence the tissue 
microenvironment (the paracrine effect). The autocrine effect comprises production 
of proinflammatory factors such as cytokines and chemokines, and matrix-
remodelling factors that are responsible for alteration of the tissue microenvironment 
enhance cancer cell proliferation, angiogenesis, as well as metastasis. There are 
anti-inflammatory factors that are released by the senescent cells which encourage 
the elimination of tumor cells by marking them for immunoclearance. On the other 
hand, as a paracrine effect, some factors exert tumor promoting activity on nearby 
cancer cells by increasing tumorigenesis. Figure adapted from Lee et al. 201471. 
Recently, SASP has been compared with an evolutionarily conserved mechanism 
that governs cellular competition and bi-directional paracrine signaling amongst 
weaker and stronger cells72. This could be an effort to maintain tissue homeostasis. 
OIS cells appear to be surrounded by immune cells expressing p16INK4a and p21CIP1, 
observed in in vivo models. These surrounding cells make it difficult to propose a 
senescence associated marker expression in tissues. It also complicates the 
interpretation of how the OIS cells in vivo affect the surrounding stromal environment 
and immune response. Besides, most of the known SASP components have many 
others functions apart from senescence, for e.g. in acute bacterial or viral infections, 
inflammation, wound healing and growing malignancies73. IL-6, which is considered 
as one of the signature SASP components have a much more pronounced 
expression induced by some acute inflammation as compared to in senescence74,75. 
Currently, a signature to distinguish between senescence and other forms of cellular 
stresses characterized by NF-κB is unavailable73.  
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 1.6 Proteotoxicity in senescence 
To sustain harmony between the components of the complex proteostatic network, a 
cell maintains proper protein homeostasis or proteostasis. An imbalance in any 
branch of the complex network can have dire consequences. In general, it could lead 
to the breakdown of the proteostatic network and contribute towards numerous 
metabolic, cardiovascular, oncological and neurodegenerative diseases. Therefore, 
it is important to understand the proteostatic network regarding different biological 
contexts and the implication of proteostasis across various diseases.  
The cell experiencing proteotoxicity withstands the stress via proper autophagic 
activity in the cytosol or the ER, since large amounts of proteins are synthesized 
there76. An imbalance in these autophagic and ER systems results in an 
incompetency to clear the misfolded or unstable proteins inside the cells. The 
accumulation of such proteins leads to cytotoxic effects77. In aging cells, a decline in 
coordination of the proteostatic network has been shown to increase the burden of 
misfolded proteins without efficient protein synthesis, processing, localization and 
degradation pathways78,79 Apart from aging, cellular senescence (TIS and OIS) with 
massive SASP requires increased protein production, and thereby promotes the 
chance of misfolded protein formation. Dörr and colleagues established that this 
protein production is responsible for TIS associated higher glucose utilization and 
ATP production. They also linked this observation to SASP, since models lacking a 
strong SASP response did not present with these features. Moreover, only SASP 
producing TIS cells exhibited ER-stress-UPR-ubiquitination autophagy cascade. 
These features together are representative of proteotoxicity70. 
Mammalian target of rapamycin complex 1 (mTORC1) regulates autophagy. 
mTORC1 inactivates ATG13 and ULK1 by phosphorylating them, depending on the 
nutrition levels80. Starvation or decreased glucose and high AMP levels lead to 
autophagy induction, via AMPK and repression of the mTORC1 activity. Whereas, 
increased levels of amino acids, insulin and insulin-growth factor 1 inhibit autophagy 
via the PI3K/AKT/mTORC1 pathway induction81. In senescent primary human 
fibroblast, there is a significant upregulation of the autophagosomal marker LC3-II82. 
In different cellular contexts, mTOR inhibition has a different impact83. In OIS, SASP 
is affected by recruiting the mTOR complex to a novel sub-cellular compartment 
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called the TOR-autophagy spatial coupling compartment (TASCC)84. Inhibiting 
mTOR via rapamycin interferes with autophagy and induces senescence in 
radioresistant cancer cells in a xenograft model, but suppresses SASP85,86. Thus, 
autophagy modulates senescence and its associated cellular mechanisms. Although 
there is a considerable role of autophagy in senescence in cancer, not much is 
known about their co-dependence on each other. 
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 2 Alzheimer’s Disease 
Alzheimer’s disease (AD) is one of the primary causes of dementia in the world. AD 
can also be referred to as a protein misfolding disease due to the formation of 
abnormally folded beta amyloid (Aβ) and tau amyloid proteins in the brain. 
Characteristic features of AD include neuron loss, neuronal dystrophy, senile 
plaques, neurofibrillary tangles, and loss of synapses. Amyloid precursor protein 
(APP) is divided into smaller fragments of Aβ by enzymes such as β-secretase and 
γ-secretase. Accumulation of these Aβ peptides triggers neuron degeneration87. The 
underlying mechanism responsible for such pathophysiology remains to be resolved. 
Although there is evidence which supports that plaques formed by the accumulation 
of Aβ are central to the AD pathology, it does not support all the aspects of AD. 
There is encouraging indication that Aβ or amyloid independent factors add to the 
pathogenesis of the disease, such as alternative AD-related genes (like 
Apolipoproteins E and microtubule-associated protein tau), elevated autophagic 
burden, inflammation, and oxidative stress88. This suggests that there may be more 
than one biological process that can lead to AD. 
AD is classified depending on the age of onset of the disease. Early onset AD 
(EOAD) (also known as Familial AD or FAD) occurs before the age of 65 years and 
is observed in approximately 5% of all cases. On the other hand, late-onset AD 
(LOAD) occurs at 65 years or later, and is observed in more than 95% of the 
affected cases. There is a difference between the pathology of the two types of ADs. 
EOAD results in a more rapidly progressing AD and follows a Mendelian pattern of 
inheritance. APP along with Presenilin 1 (PSEN1) and Presenilin 2 (PSEN2), which 
are components of the γ-secretase enzyme, are known to be involved in Aβ 
generation, which is the central component involved in the pathophysiology of 
EOAD. In more than 85% cases of EOAD, a mutation is observed in these three 
genes. Therefore, these three are useful as diagnostic biomarkers of EOAD. On the 
contrary, LOAD follows a non-Mendelian pattern. It is observed that the probability to 
develop LOAD is twice if a first-degree relative has LOAD87. 
Although the physiological function of APP is largely unknown, it is proposed to be 
involved in trafficking, neurotrophic signaling, cell adhesion and cell signaling89–91. 
PSEN1, which is a critical component of the γ-secretase complex, is known to play 
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an important role in autophagic vacuole clearance92. Induction of autophagy in 
mouse fibroblasts by rapamycin or nutrient deprivation result in translocation of the 
γ-secretase complex from the endosomal/ER pool to the autophagic vacuoles and 
the γ-secretase activity in these vacuoles increase the production of Aβ93. Therefore, 
increased residence time of these autophagic vacuoles in cells increases the chance 
of Aβ production and exocytosis. In AD mouse models, over expressing the FAD-
related mutant human PSEN1 and APP, macroautophagy leads to the accumulation 
of Aβ in the autophagic vacuoles of the affected neurons94,95. In APP/PSEN1 
transgenic mice (harboring Thy1- APPKM670/671NL and Thy1-PS1L166P 
mutations), autophagic vacuoles appear in neurons at a younger stage before Aβ 
plaques appear. This suggests that macroautophagy is an early response and is 
followed by amyloid deposits and not the other way around93. 
Autophagy is also an integral part of senescence and possibly these AD inducing 
genes could also be involved, directly or indirectly, in senescence. 
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 2.1 APP processing 
APP can be proteolytically processed via two alternative pathways- the 
amyloidogenic and the non-amyloidogenic pathway96,97(Figure 4). In amyloidogenic 
pathway, APP is cleaved by the enzyme BACE (-site APP cleaving enzyme) at the 
-secretase site98. This results in a soluble -APP fragment (sAPP) and the C99 
fragment, which is a 99-amino acid C-terminal fragment (CTF). C99 is attached to 
the membrane but can be subsequently cleaved by a γ-secretase complex99. This 
process takes place in the intramembrane region and releases the A peptide. A 
peptides can further aggregate extracellularly to form plaques. On the other hand- 
via the non-amyloidogenic pathway, APP is first cleaved by a -secretase that 
cleaves within the A region, and releases a soluble 110-120 kDa -cleaved APP 
fragment (sAPP)100. Hence, the resulting CTF, with 83-amino acids, is shorter and 
known as C83. C83 can be further cleaved by γ-secretase to release p3. In both the 
pathways, cleavage of their respective CTF by γ-secretase also releases APP 
intracellular domain fragment (AICD) 90,101. These various components formed via 
APP processing may contribute to both disease and normal physiology. 
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Figure 4: Proteolytic processing of APP. Two major pathways of APP processing- 
the amyloidogenic and the non-amyloidogenic pathway. -secretase cleaves APP 
resulting in the subunits sAPP and C99 in case of the amyloidogenic pathway, and 
-secretase cleaves APP resulting in the subunits sAPP and C83 in case of the 
non-amyloidogenic pathway. In both the pathways, the γ-secretase complex cleaves 
the APP-CTF into AICD and A (from C99) and p3 (from C83) peptides. Figure 
adapted from Nicolas et al. 2014. 
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 2.2 Gamma-secretase complex 
γ-secretase, an aspartyl protease, is a complex enzyme with over 90 substrates102. It 
is composed of 4 subunits forming a 1:1:1:1 heterodimer, which is PSEN, nicastrin 
(NCSTN), anterior pharynx-defective 1 (APH-1) and presenilin enhancer 2 
(PEN2)103–107. PSEN is the catalytic subunit for -secretase108–110. In mammals, there 
are two isoforms, PSEN1 and PSEN2. PSEN mutations lead to either a change in 
the A1-42/ A1-40 peptides ratio or an increase in the overall A levels
111,112. These 
features are associated with EOAD113. But it is still unclear whether the loss of or 
gain of function of PSEN1 mutation is involved in AD114,115. 
γ-secretase is a tightly regulated enzyme and only a small fraction of its complexes 
are active at a time116–118. All the subunits are present in the active complexes, and 
overexpression of all the subunits is necessary for increasing γ-secretase activity119. 
However, in vivo, overexpressing PSEN alone leads to increased enzyme activity120. 
This suggests that regulation of γ-secretase is more complex in vivo and probably 
has many layers of functional regulations in the context of specific tissues or 
diseases 121. 
Before the discovery of γ-secretase, some proteasome inhibitors were tested in 
APP-transfected cells where they resulted in the accumulation of APP-CTFs and 
inhibited the production of p3 and A122–124. Initial studies of a γ-secretase inhibitor, 
DAPT, reported that γ-secretase inhibition resulted in potential inhibition of A 
production in cells. Much higher oral doses of the inhibitors, as compared to in vitro 
studies, were required to observe 50% decline in the A levels in the brains of young 
APP transgenic mice125. Subcutaneous application of the drug affected the A levels 
in plasma and CSF, decreasing it in a dose-dependent manner. But this only 
resulted in reduced A levels in the brains of the younger mice and not in the older 
mice126. None of the tested inhibitors succeeded in suppressing A plaques formed 
in the brains of the adult animal models. 
Semagacestat is a γ-secretase inhibitor that advanced into phase III clinical trials. 
This compound resulted in a reduction in the steady-state levels of A in the plasma, 
but not in the cerebrospinal fluid127–129. In the phase III of the trial, drug 
administration led to severe gastrointestinal toxicity, immunomodulation, and skin 
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cancer. These effects are indicative of an impaired Notch activity. Another intriguing 
finding was that the cognition of drug-treated group was worse than the placebo-
treated group in AD patients. Therefore, apart from its nonselective effect on Notch 
signaling, this suggests a potential negative impact of lowering brain A levels, or 
more so of increasing the APP-CTF levels130. Thus, despite of being a lucrative 
target for AD treatment, γ-secretase inhibition has not succeeded as a viable 
approach due to its undesirable off-target effects. An approach that specifically and 
exclusively targets APP processing needs to be further elucidated. 
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 3 Senescence and Alzheimer’s disease 
Senescent cells are a component of age-related pathologies, such as 
neurodegenerative diseases and malignancies131. This suggests that these 
pathologies might be driven by features associated with senescent cells132. Protein 
synthesis is one such process that is regulated by checking for misfolded proteins. 
The cellular proteome clears these misfolded proteins by correcting or degrading 
them. Age impairs cellular activity, which leads to misfolded proteins133. The 
accumulation of oxidative modifications such as carbonylation, oxidized methionine, 
and glycation, along with an increase of cross-linked and aggregated proteins in 
aged tissues suggest that these features significantly contribute to their functional 
decline. Aged tissues also associate with less catalytically active enzyme 
populations134. 
According to the senescence hypothesis of Alzheimer’s disease progression, the AD 
associated factors induce stress to the neurons, which in turn influence their function 
and survival. Once the stress inducing factors surmount the cell’s threshold to 
endure the given stress, senescence pathways are triggered. There is crosstalk 
between the pathways involved in senescence and the APP proteolytic system. 
Senescence-associated signaling has also been shown to regulate APP 
proteolysis135. 
In APP overexpressing EOAD, there is a potential imbalance between functions of 
PSEN, depending on its activity in the γ-secretase complex. An increase in demand 
for PSEN activity in one system leads to low availability of PSEN for its roles in other 
proteolytic systems such as Notch, LRP and CD44. This mimics some of the 
changes to PSEN function (associated with the γ-secretase complex) according to 
the PSEN hypothesis136–138. The hypothesis states that mix of gain and loss of 
functions of PSEN1 and to some extent PSEN2, dependent or independent of its γ-
secretase functions, contribute to the progression of AD114. There are mutations of 
the PSEN gene that lead to an increased affinity of γ-secretase towards APP. This 
results in elevated production of Aβ in general, or modification of the ratio of 
fragments Aβ(1-40) and Aβ(1-42) due to altered cleavage, causing Aβ to accumulate 
and form plaques113,139. However, the clear role of Aβ in affecting the 
neuropathology and cognitive status of an AD patient is not known140. An 
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interpretation of this observation could be the loss of alpha pathway cleavage within 
the APP proteolytic system. That is, if the mutations result in loss of PSEN function, 
it could affect the balance between alpha and beta pathways, which could lead to 
loss of protective function. Alternately, the ratio between different Aβ fragments 
could be responsible for different signaling functions114,141–143. This suggests that 
there could be many different causes and contributors of the AD biology, which 
results in a complicated AD pathology. 
Notch has myriads of functions and is also involved in cancer, where it functions like 
a tumor suppressor when affiliated with p53 activation. Together, Notch and p53 
suppress proliferation by their role in regulating differentiation, senescence or 
apoptosis144. APP has been proposed to be involved in regulation of notch 
processing because of cross-talk in between them145–147. Hence, APP could have an 
impact on progression of the disease due to altered Notch signaling, and be involved 
in determining the fate of the cells by regulating senescence and cell death148,149. 
Spontaneously occurring LOAD could be a result of progressing cellular senescence 
in the brain, and this could be due to accumulation of ageing features leading to the 
pathology. The factors associated with LOAD are mostly involved in cell signaling 
pathways responsible for neuronal survival and act to induce stress in the cell. 
Senescence pathways are triggered once these cells cannot negate the effects of 
stress anymore. When the neuroprotective mechanisms are unable to cope with 
stresses associated with the disease, senescence progresses135. 
It has been postulated that once these cells undergo senescence, Aβ is released as 
a protective response, to induce ROS activation and induce factors such as IL-1 and 
IL-6 from the neighboring senescent cells. Aβ can hence be used as a marker for 
senescence in this scenario. As the senescence in the neurons progresses, there is 
an inevitable loss of neural network function and failure of cognitive processes. 
Alternatively, in the case of EOAD, the cells undergo premature senescence due to 
the stress induced by the imbalance between APP/PSEN. This imbalance nudges 
the cell towards senescence. The disease hence progresses with senescence. In 
familial forms of AD, the mechanisms of neuroprotection might be exhausted earlier 
and the stress is elevated135. 
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Senescence also strengthens the association between cancer and 
neurodegenerative pathways150–155. Therefore, it is possible that senescence may 
have the possibility to lay the groundwork for AD progression156–158. This might be 
pivotal to use the knowledge from one discipline for the benefit of the other. 
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HYPOTHESIS 
Preliminary data from our lab demonstrated that AD genes were up regulated in 
case of TIS of Eμ-myc-driven B-cell lymphomas with bcl2 overexpression. According 
to the senescence hypothesis of AD, factors associated with Alzheimer’s can trigger 
senescence135. Proteotoxic stress has been reported in both AD and 
senescence70,159. This led us to hypothesize that proteotoxicity might be the common 
denominator of the two pathologies and players of the Alzheimer’s pathology could 
be the contributing factor of senescence-related proteotoxicity. 
AIM 
To explore the link between cellular senescence and Alzheimer’s disease (AD), and 
to provide novel insights into both pathologies, using Eμ-myc-driven B-cell 
lymphomas. This may lead to re-purposing of therapeutic strategies across distinct 
disease entities to move cancer research forward. 
 
MATERIALS & METHODS 
 25 
 
MATERIALS AND METHODS 
 1 MATERIALS 
 1.1 Chemicals 
Name Company 
30% Acrylamide/Bis-acrylamide Carl Roth 
Adriamycin   Sigma 
Agar   Carl Roth 
Agarose Carl Roth 
Albumin Fraktion V Carl Roth 
Ammoniumperoxisulfat (APS) Carl Roth 
Ampicilin, sodium salt   Carl Roth 
Blasticidin   Invitrogen 
Bromphenol blue   Euro-bio 
Calcein   Sigma 
Calcium chloride (CaCl2)   Carl Roth 
Chloroform Merck 
Chloroquine-diphosphate   Sigma 
DAPI   Sigma 
Diethyl pyrocarbonate (DEPC) Sigma 
Dimethylsulfoxid (DMSO)   Merck 
dNTPs   Biochrom 
Dulbecco ́s MEM   Invitrogen 
DTT   Eurobio 
ECL reagent Millipore 
Ethylenediaminetetraacetate (EDTA) Carl Roth 
Ethanol, absolute Carl Roth 
Ethidium-bromide powder   Sigma 
Fetal bovine serum (FBS) Biochrom 
Formaldehyde solution 37%   Carl Roth 
Gel Ruler 1-kb ladder plus   Fermentas 
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Glucose   Carl Roth 
Glutaraldehyde Carl Roth 
Glycerol   Carl Roth 
Glycine   Serva 
H2O2 Invitrogen 
Hydrocloric acid, HCl   Sigma 
HEPES   Carl Roth 
Hygromycin   Invitrogen 
Iscove's modified Eagle's media Invitrogen 
L-Glutamine (solution)   Invitrogen 
L-Glutamine (powder)   Biochrom 
Magnesium chlorid [MgCl2x6H2O] Carl Roth 
β-Mercaptoethanol   Carl Roth 
Methanol   Carl Roth 
Microscopy Aquatex Merck 
Milk powder   Carl Roth 
Mowiol® 4-88 Merck 
Nonident 40 (NP-40)   Fluka   
PageRuler Plus Prestained Protein Ladder Thermo Scientific 
Paraformaldehyde Sigma 
Penicillin-streptomycin   Biochrom 
Pentameric formyl thiophene acetic acid 
(PFTAA) 
Gift from Prof. Dr. Frank 
Heppner 
Phosphate Buffered Saline (PBS) Carl Roth 
Phenylmethylsulfonylfluoride (PMSF) Sigma 
Polybrene   Sigma 
Potassium bicarbonate [KHCO3] Sigma 
Potassium ferricyanide [K3Fe(CN)6] Sigma 
Potassium ferrocyanide [K4Fe(CN)6x3H2O] Sigma 
Potassiumchloride (KCl) Sigma 
Potassiumacetate (KAc)   Carl Roth 
ProLong™ Diamond Antifade Mountant Thermo Scientific 
Propidium iodide   Sigma 
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Protease inhibitors tablet   Roche 
Puromycin Calbiochem 
ROTI-prestained   Invitrogen 
RotiQuant, Bradford reagent   Carl Roth 
RPMI 1640   Invitrogen 
Salmon sperm DNA   Invitrogen 
SDS 2326.2 ROTH   Carl Roth 
Sodiumchloride (NaCl)   Carl Roth 
Sodium citrat [C6H5Na3O7x2H2O] Carl Roth 
Sodium-desoxycholate   Sigma 
Sodiumfluoride (NaF)   Sigma 
Sodiumhydroxide (NaOH) Carl Roth 
Sodiumorthovanadate   Sigma 
Sodium pyrophosphate [Na4P2O7x10H2O] Sigma 
Tris(hydroxymethyl) base   Carl Roth 
TEMED   Sigma 
Triton-X 100   Merck 
TRIZOL   Invitrogen 
Trypan-blue solution   Sigma 
Trypsin-EDTA   Carl Roth 
Trypton/Pepton   Carl Roth 
Tween 20   Carl Roth 
Vecta-Shield, mounting medium   Vector 
X-Gal   Carl Roth 
Xylene-cyanol   Eurobio 
Yeast extract   Carl Roth 
2-propanol   Sigma 
5-bromo-2'-deoxyuridine (BrdU) Sigma 
 1.2 Equipments 
Name Company 
Avanti J-26XP Ultra-Speed centrifuge Beckman Coulter 
Bacteria shaker Innova 4000 New Brunswick Scientific 
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Bioanalyzer 2100 Agilent Technologies 
Cell culture dishes and falcons TPP 
Cell culture incubator Heraeus 
Centrifuge 5417R Eppendorf 
Centrifuge Rotina 35R Hettich 
ChemiDoc MP Imaging System Bio-Rad 
Chemocam imager Intas 
Cryotubes Sefar company 
Cyto chambers Hettich 
FACS Calibur Becton Dickinson 
Fluorescence microscope Zeiss 
Fluorescence microscope BZ-9000 Keyence 
gentleMACSTM Miltenyi 
Guava® easyCyte flow cytometer Merck 
LUNA™ Automated Cell Counter Logos biosystems 
Megafuge 1.0 R Eppendorf 
Microscope Zeiss Telaval 31 Zeiss 
Microscopy Immersion Oil Merck 
Microwave Siemens 
Mr. Frosty Freezing Container Thermo Scientific 
MSD® MULTI-SPOT Assay system Meso Scale Diagnostics 
NanoDrop ND-2000 Peqlab 
Nylon Mesh (35 μm) Simport Plastics 
PCR machine Peqlab 
pH-meter MP-220 Mettler Toledo 
Pipettes Eppendorf 
Polystyrene tubes BD Falcon 
PVDF membrane (Immobilon-P) Millipore 
Rotilabo Filter sterile (0.22 μM PVDF) Carl Roth 
Rotilabo Filter sterile (0.45 μM PVDF) Carl Roth 
Scalpel for single-use Feather 
SDS-PAGE Chamber C.S.B. Scientific 
Semi-dry transfer system Biorad 
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Serological pipettes Falcon Becton Dickinson 
StepOnePlus ™ Real-Time PCR System Applied Biosystems 
Thermo-cycler PCR machine Peqlab 
Thermomixer Peqlab 
UV detection system Biometra T13 
Whatman paper (3MM) Schleicher-Schuell 
 
 1.3 Antibodies 
Name Clone Number Company 
Actin 4967 Cell signaling 
Anti-β-amyloid (Purified) 4G8 Biolegend 
Anti-mouse IgG HRP NXA931 Amersham 
Anti-mouse-IgG 
AlexaFluor 488 
A11001 
 
Thermofisher Scientific 
Anti-mouse-IgG 
AlexaFluor 594 
A11005 
 
Thermofisher Scientific 
Anti-rabbit IgG HRP NA9340 Amersham 
Anti-rabbit-IgG 
AlexaFluor 488 
A11008 Thermofisher Scientific 
Anti-rabbit-IgG 
AlexaFluor 594 
A11037 Thermofisher Scientific 
APP 2452 Cell signaling 
APP 22C11 MAB348 Millipore 
APP C-termial (751-770) 171610 Millipore 
APP-C terminal A8717 Sigma 
H3K9me3 ab8898 abcam 
Ki67 SP6 Thermofisher Scientific 
LAMP2a Ab18528 Abcam 
LC3 2G6 Nanotools 
p16 (F-12) Sc-1661 Santa cruz 
p21 sc-397 Santa Cruz 
p53 phospho-S15 9284 Cell signaling 
p53 Protein (CM5) NCL-p53-CM5p novocastra 
MATERIALS & METHODS 
 30 
Psen1 Ab53717 abcam 
Psen1 (APS18) AB15458 abcam 
Ras sc-68743 Santa Cruz Biotechnology 
p62(p62/SQSTM1) 5114 Cell signaling 
Tubulin T6199 Sigma 
V-ATPase A1 (E-8) sc-374475 Santa cruz 
 
 1.4 Enzymes 
Name Company 
BamH1 NEB 
Bgl II NEB 
EcoR I NEB 
Hind III NEB 
Proteinase K   Merck 
RNAse A   Fluka 
RNAse-out RNAse Inhibitor  Invitrogen 
Superscript Reverse Transcriptase III  Invitrogen 
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 1.5 Commercial Kits 
Name  Catalog Number  Company  
Dako REALTM Detection 
System, Alkaline 
Phosphatase_RED, 
Rabbit_Mouse  
K5005 Dako 
Guava ViaCount Reagent for 
Flow Cytometry  
4000-0040  Millipore  
Immobilon Western 
Chemiluminescent AP Substrate  
P36600  Millipore  
MSD® MULTI-SPOT Assay 
System 
Aβ Peptide Panel 1 (4G8) Kit 
K15199G-1 
 
Meso Scale 
Diagnostics 
NucleoSpin Gel and PCR Clean-
up  
740609.250  MACHEREY- 
NAGEL  
ON-TARGETplus Mouse App 
siRNA: SMARTpool 
L-043246-00-0005 GE Healthcare 
Dharmacon 
ON-TARGETplus Mouse Psen1 
siRNA: SMARTpool 
L-048761-01-0005 GE Healthcare 
Dharmacon 
ON-TARGETplus Non-targeting 
Pool 
D-001810-10-05 GE Healthcare 
Dharmacon 
QIAprep Spin Miniprep Kit   27104  Qiagen  
SuperScript® III First-Strand 
Synthesis System  
18080-051  Invitrogen  
TaqMan® Gene Expression 
Master Mix  
4369016  Applied Biosystems  
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 1.6 Mouse strains 
Name Reference 
C57BL/6  Clarence Cook Little, Bussey Institute, 
Harvard University, USA, 1921  
C57BL/6 (Suv39h1 knock-out)  Peters et al, Cell 2001, IMP, Vienna, 
Austria   
C57BL/6 (p53 knock-out)  Jacks et al, Current Biology 1994, 
Whitehead institute, Cambridge, USA  
APPPS1+/- Gift from Prof. Dr. Frank Heppner 
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 1.7 Cell strains and cell lines 
Name  Description  Source  
NIH 3T3  mouse embryonic fibroblast  ATCC  
Pheonix  human embryonic kidney line  Clontech/Takara  
SH-SY5Y Human neuroblastoma cell line 
Parental and overexpressing 
APP 
Gift from Prof. Dr. 
Thomas Willnow 
Eμ-myc B cell 
lymphoma 
Murine primary lymphoma Lab made 
MEF  Murine embryonic fibroblast  Lab made  
 
 1.8 Bacteria 
DH5α E.coli Genotype: F ́ proA+B+ lacIq ∆ lacZ M15/ fhuA2 ∆(lac-proAB) 
glnV gal R(zgb-210::Tn10)TetS endA1 thi-1 ∆(hsdS-mcrB)5  
 
 1.9 Plasmids 
Name Backbone 
MSCV-Bcl2-GFP MSCV-GFP 
MSCV-Bcl2-puro MSCV-puro 
pSR-shAPP-puro  pSuper-retro-puro  
pSR-shPsen1-puro pSuper-retro-puro  
MSCV-IκBΔN-GFP MSCV-GFP 
MSCV-Ras-puro MSCV-puro 
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 1.10Primers 
Name Sequences 
Short hairpin APP Forward:  
GATCCCC CGTTACAGTAGCACTCCTAAT 
TTCAAGAGA ATTAGGAGTGCTACTGTAACG 
TTTTTA 
Reverse:  
AGCTTAAAAA CGTTACAGTAGCACTCCTAAT 
TCTCTTGAA ATTAGGAGTGCTACTGTAACG 
GGG 
Short hairpin Psen1 Forward: GATCCCC 
CCCAAAGTTTACTCAAGACTA TTCAAGAGA 
TAGTCTTGAGTAAACTTTGGGTTTTTA 
Reverse: 
AGCTTAAAAACCCAAAGTTTACTCAAGACTA 
TCTCTTGAA TAGTCTTGAGTAAACTTTGGG 
GGG 
Real-Time PCR primers  
Human APP Taqman primer from Applied Biosystems  
Cat. Hs00169098_m1 
Human Psen1 Taqman primer from Applied Biosystems  
Cat. Hs00997789_m1 
Mouse Adam10 Taqman primer from Applied Biosystems  
Cat. Mm00545742_m1 
Mouse Aph1a Taqman primer from Applied Biosystems  
Cat. Mm00778687_s1 
Mouse Apoe Taqman primer from Applied Biosystems  
Cat. Mm01307193_g1 
Mouse APP Taqman primer from Applied Biosystems 
Cat. Mm01344172_m1 
Mouse Calm1 Taqman primer from Applied Biosystems  
Cat. Mm01336281_g1 
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Mouse Casp3 Taqman primer from Applied Biosystems  
Cat. Mm01195085_m1 
Mouse Casp7 Taqman primer from Applied Biosystems  
Cat. Mm00432322_m1 
Mouse Ece1 Taqman primer from Applied Biosystems  
Cat. Mm01187104_m1 
Mouse Gsk3b Taqman primer from Applied Biosystems  
Cat. Mm00444911_m1 
Mouse Htt Taqman primer from Applied Biosystems  
Cat. Mm01213820_m1 
Mouse Ide Taqman primer from Applied Biosystems  
Cat. Mm00473077_m1 
Mouse IL23a Taqman primer from Applied Biosystems  
Cat. Mm00518984_m1 
Mouse IL6 Taqman primer from Applied Biosystems  
Cat. Mm00446190_m1 
Mouse LPL Taqman primer from Applied Biosystems  
Cat. Mm00434764_m1 
Mouse LRP1 Taqman primer from Applied Biosystems  
Cat. Mm00464608_m1 
Mouse Ncstn Taqman primer from Applied Biosystems  
Cat. Mm01293323_g1 
Mouse Psen1 Taqman primer from Applied Biosystems  
Cat. Mm00501184_m1 
Mouse Psen2 Taqman primer from Applied Biosystems  
Cat. Mm00448406_m1 
Mouse Psenen Taqman primer from Applied Biosystems  
Cat. Mm00727761_s1 
Mouse Psmb8 Taqman primer from Applied Biosystems  
Cat. Mm00440207_m1 
Mouse Sort1 Taqman primer from Applied Biosystems  
Cat. Mm00490905_m1 
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 1.11Media and Solutions 
1.11.1 Media 
Name Ingredients 
LB Medium 10 g tryptone   
5 g yeast extract   
10 g NaCl   
1 L dH2O, pH 7.0 
store at +4°C   
LB agar plate  
 
LB-medium+15 g Agar   
After autoclaving, cool to 36pprox.. 
55°C,  
add antibiotic and pour into petridish  
store at +4°C   
B Cell medium  
 
DMEM + IMDM (1:1)   
+ 10% FCS   
+ Penicillin-streptomycin (100 U/ml)  + 
 4 mM L-Glutamine   
+ 25 μM β-mercaptoethanol   
store at +4°C   
DMEM medium  
 
DMEM   
+ 10% FCS   
+ Penicillin-streptomycin (100 U/ml)  
store at +4°C   
Freezing medium  
 
FCS + 10 % DMSO   
store at +4°C  
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1.11.2 Solutions and Buffers: 
Transfection solutions    
2 M CaCl2   2.99 g in 10 mL dH2O, store at -20°C  
2x HBS (Hepes buffered saline)  280 mM NaCl   
10 mM KCl   
1.5 mM Na2HPO4 x 2H2O  
12 mM Dextrose   
50 mM HEPES   
100 mL dH2O, pH 7.05 
100 mM Chloroquine  0.516 g Chloroquine diphosphate 
10 ml dH2O   
store at -20°C 
Western blotting solutions   
Protein lysis buffer (NP-40)  1% NP-40  
50 mM Tris-HCl pH 7.4  
150 mM NaCl  
5 mM MgCl2  
proteinase inhibitor cocktail (Roche)  
phosphatase inhibitor cocktail (Roche)  
store at -20°C  
SDS sample buffer  1 ml 0.5 M Tris-HCl (pH 6.8)  
0.8 ml Glycerol  
1.6 ml 10% SDS  
0.4 ml 14.3 M β-mercaptoethanol  
0.4 ml of 1% Bromephenol blue  
store at -20°C  
0.5 M Tris-HCl pH 6.8  6 g Tris base, pH 6.8, 
upto100 ml dH2O  
1.5 M Tris-HCl, pH 8.8  27.23 g Tris base, pH 8.8, 
upto 100 ml dH2O  
10% APS  1 g Ammonium peroxysulfate  
in 10 ml dH2O  
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10x Running buffer (pH 8.3)  30 g Tris base   
144 g Glycine   
10 g SDS   
upto 1 L dH2O pH 6.8   
Transfer Buffer  2.9 g Tris base   
14.5 g glycine   
200 ml methanol   
upto 1 L dH2O, store at 4°C  
25x TBS  60 g Tris base  
200 g NaCl  
9.5 ml 10 N HCl  
upto 1 L dH2O  
1x TBS-Tween (TBS-T)  0.2 % Tween 20 in TBS  
Blocking solution  5 % dry milk in 1x TBS-T,  
freshly prepared 
SA-β-gal assay solutions   
PBS / MgCl2  
 
1 mM MgCl2 in 1 x PBS 
pH 5.5 for murine sample 
pH 6.0 for human sample 
Fixation solution  0.25 % Glutaraldehyde  
2% Paraformaldehyde   
in PBS, freshly prepared 
20x Potassium cyanide (KC) stock  20 mg K3Fe(CN)6  
1.050 mg K4Fe(CN)6 x 3H2O 
 in 25 ml 1 x PBS   
store at 4°C in the dark   
40x X-Gal solution  40 mg X-Gal in 1 ml DMFO  
Store at -20°C  
Staining solution  9.25 ml PBS / MgCl2   
0.5 ml 20 x KC solution  
0.25 ml 40 x X-Gal solution 
freshly prepared  
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Immunofluorescent (IF)/ 
Immunohistochemistry (IHC) 
staining  
 
Fixation solution  4% Paraformaldehyde in 1 x PBS 
freshly prepared    
Permeabilization solution  0.2%Triton X-100 in 1 x PBS   
Blocking solution  1% BSA in 1 x PBS  
Washing buffer  0.01% Tween 20 in 1x PBS  
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 2 METHODS 
 2.1 Molecular Cloning of DNA construct 
2.1.1 PCR: amplification of DNA 
PCR primers were designed using online tools and used for their respective DNA 
targets. The total volume of PCR reactions was 50 μl.  
 
Components Quantity 
Template DNA 10- 100 ng  
10x PCR buffer with MgCl2  5μl  
dNTP mix (10 mM each)  1μl  
Sense primer (10 μM)   1μl (10 pM)  
Antisense primer (10 μM)   1μl (10 pM)  
Taq or Pfu Polymerase (5 U/μl)  1μl  
dH2O  Add dH2O upto 50 μl.  
 
Conditions Temperature Duration 
Initial denaturation  94°C   
30-35 cycles  94°C  30 sec  
 48-60°C  30 sec  
 72°C  1 minute/kb DNA  
Final extension  72°C   10 min   
Hold  4°C  ∞  
 
2.1.2 PCR product purification and digestion  
NucleoSpin PCR clean-up kit was used to clean up the PCR products as per the 
manufacturer’s protocol. This was followed by digestion of the product using the 
respective restriction enzymes for a minimum of 6 hours, at 37 °C. 
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 2.2 Ligation of DNA fragments 
Purified linearized vector (~50 ng) and PCR product were used in a ratio of 1:3. T4 
ligase was used for the ligation reactions (10 μl), which were carried out according to 
the manufacturer’s instructions.  
2.2.1 Bacteria transformation 
Ligation product (10 μl) was added to 50 μl competent DH5α E.coli, in a 1.5 ml 
eppendorf tube. This mix was incubated on ice for 20 minutes. The cells were heat 
shocked at 42°C for exactly 90s and immediately put on ice for 2 minutes. After 
adding 1 ml LB medium, the tube was incubated in 37°C shaker for 45 minutes. The 
bacteria was then pelleted and plated on LB-agar plates with 100 μg/ml ampicillin. 
The plates were incubated at 37°C overnight.  
2.2.2 Plasmid preparation: mini-preparation and maxi-preparation 
Individual colonies were picked and incubated in individual tubes with 3 ml LB 
medium (100 μg/ml ampicillin) at 37°C overnight. Bacteria was centrifuged at 3000 
rpm (5 minutes, 4°C) and pellet was resuspended, lysed, precipitated by sequentially 
adding 100 μl ice-cold Solution I, 200 μl freshly prepared Solution, 150 μl of ice-cold 
Solution III. After centrifugation (14000 rpm, 10 minutes, 4°C), supernatant was 
transferred to a new Eppendorf tube and 1 ml of ethanol was added to precipitate 
DNA. After vortexing and centrifugation (14000 rpm, 10 minutes, 4°C) the pellet was 
washed with 1 ml of 70% ethanol. DNA was air-dried and dissolved in 30 μl dH2O.  
Maxi-preparation of plasmid was made using the Invitrogen maxi-prep kit, following 
the manufacturer’s protocol.  
2.2.3 DNA sequencing 
The DNA sequencing was delegated to Source BioScience LifeSciences (MDC, 
Berlin). 
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 2.3 Cell culture 
2.3.1 Thawing and freezing of cells  
Thawing: Cryovials with frozen cells were removed from liquid nitrogen or -80°C, 
and placed into a 37°C water bath. The thawed cells were transferred to 9 ml fresh 
growth medium and were pelleted by centrifugation at 1,200 rpm for 5 min. All these 
steps were carried out swiftly, to minimize the toxic effects of DMSO on the cells. 
The cell pellet was resuspended, seeded on tissue culture dishes and cultivated in 
the incubator. 
Freezing: Adherant cells were trypsinized, whereas, for suspension cells, the cells 
were collected from the culture dish and transferred to the falcon tubes for 
centrifugation, pelleted down and resuspended in freezing medium and transferred 
into sterile 1.5 or 2 ml cryovials. The cells were then put into “Mr. Frosty” box and 
immediately transferred to -80°C freezer. For long-term storage, cells were stored in 
liquid nitrogen.  
2.3.2 Adherent cell culture 
Cancer cell lines, NIH 3T3 and Phoenix cells were cultivated at 37°C in an incubator 
with 5% CO2, 20% O2, 95% humidity atmosphere. Murine embryonic fibroblasts 
were cultivated at 37°C in an incubator with 5% CO2, 3% O2, 95% humidity 
atmosphere. Cells were grown in tissue culture treated petri-dishes. Cell culture 
media was renewed every 2-3 days or as required. Almost confluent (80-90%) grown 
cells were split to new dishes to maintain the cells in log phase. For splitting of 
adherent cells, medium was removed and cells were washed twice with PBS. 
Trypsin/EDTA solution was added and the plate was incubated at 37°C for several 
minutes to detach the cells. Adding fresh medium inhibited trypsinization due to the 
presence of serum. Cells were mixed well and seeded in new dishes. DMEM 
medium was used for the culturing of all the adherent cells. 
2.3.3 Suspension cell culture 
Mouse Eμ-myc B cell lymphomas were also cultivated at 37°C in an incubator with 
5% CO2, 20% O2, 95% humidity atmosphere. Cells were grown in petri dishes lined 
with senescent NIH 3T3 cells. To senesce NIH 3T3 cells, they were irradiated with 
30 Gy of ionizing radiation and plated in tissue culture treated petri dishes as per the 
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protocol for adherent cell culture mentioned above. These cells were grown 
overnight and seeded in new culture dishes with the confluency of 106 cells per well 
of a 6 well plate in B cell medium. After another overnight incubation, allowing the 
cells to adhere to the plate, and release cytokines and chemokines conducive for 
culturing of primary murine lymphoma, lymphoma cells were added to these wells.  
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 2.4 Cell and Tissues 
2.4.1 Primary MEF isolation 
Wild-type primary MEFs were isolated from E13.5 embryos by following standard lab 
protocol.  
2.4.2 Primary lymphoma isolation 
C57BL/6 background Eμ-myc transgenic mice with desired phenotype were 
monitored for lymphoma onset. The mice were sacrificed when the lymphomas 
became greater than 5mm in diameter. The enlarged lymph nodes were excised 
after CO2 euthanasia of the mice. Single cell suspensions were produced using the 
gentleMACSTM, Miltenyi instrument. For histopathological analysis, the lymph nodes 
were snap-frozen or formalin-fixed as described previously32,70.  
2.4.3 Harvesting brain from APPPS1 transgenic mice 
Heterozygous APPPS1 +/- transgenic mice (termed as APPPS1) were used as a 
mouse model of Alzheimer’s disease. The APP and PS1 transgene refer to Thy1- 
APPKM670/671NL and Thy1-PS1L166P mutations, respectively. These mice were 
bred in the lab of Prof. Dr. Frank Heppner, Department of Neuropathology, Charité – 
Universitätsmedizin Berlin. The brains were harvested from these mice along with 
the brains of age matched APPPS1 -/- littermate controls. The brains were harvested 
and fixed in the lab of Prof. Heppner, and were sectioned in our lab for staining. 
In these transgenic mice there is an onset of cerebral β-amyloidosis in the frontal 
cortex, as early as two months of age. This is followed by appearance of small 
amyloid plaques. 
 2.5 Cell transfection and infection 
Low passage Phoenix cells were grown in a 10 cm petri dish up to a density of about 
70%. 20 μg retroviral plasmid, 15 μg helper plasmid and 62.5 μl CaCl2 were mixed 
in a Polystyrene, round bottom tube and adjusted with dH2O to up to 500 μl. To this, 
500 μl 2x HBS was added dropwise, with constant agitation (gentle air bubbles). 
DNA precipitation occurs within 5 minutes at RT (mixture gets milky and cloudy). 
This precipitate was added carefully and dropwise to Phoenix cells, which have fresh 
10 ml DMEM medium with 25 μΜ chloroquine. After 12 hour incubation, medium 
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including the precipitate was replaced with 4-5 ml of DMEM medium (B cell medium 
for lymphomas) for collecting virus supernatant.  
To be transduced cells are seeded appropriately, such that they remain in the log 
phase throughout the transduction. The virus supernatant was collected after 
approximately 24 hours after the medium was replaced. 4 μg/ml polybrene was 
added to the supernatant and transferred to the cells to be transduced. New medium 
(4-5 ml) was added to the Phoenix cells for the next round of infection. The cells 
were incubated and grown under standard conditions. 
After 12 hours of incubation, the second virus supernatant was harvested according 
to the procedure above, and supplemented with polybrene and added to the cells. 
After spinoculation of the plates (1500 rpm, 10 minutes, 32°C), cells were incubated 
and grown until the next round of transduction. In addition, new medium was added 
to the Phoenix cells for the next round of transduction. The third and fourth virus 
supernatants were collected 12 hours and 24 hours later according to the procedure 
above.  
12 hours after the last transduction, old medium was removed from the cells and 
fresh DMEM (BCM) medium was added. Cells were grown for approximately 24 
hours to allow cells to express the gene of interest. Cell population was selected with 
puromycin (~2 days) or blasticidin (~5 days) until non-transduced cells were 
completely dead. 
 2.6 Cell viability, Apoptosis and senescence 
2.6.1 Cell number and cell viability 
Cells were harvested and resuspended in a small volume of 1 x PBS (e.g. 500 μl). 
The trypan blue solution was added as 1:1. 10 μl was transferred to the 
hemocytometer and checked for equal distribution of the cells. For viability 
assessment and cytotoxicity assays, at least 200 cells were counted in total (dead 
and alive). Percentage of viability was indicated as the ratio of living cells to the 
whole cell number. For total cell number and growth analysis, all viable cells in 16 
quadrants of the big 4-square-field were counted and number of living cells in culture 
was assessed by the following calculation: cell number / ml = total number of cells 
alive in 16 quadrants x dilution factor x 104.  
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Alternatively, cells were counted using the LUNA™ Automated Cell Counter. The 
cells were diluted with trypan blue, 1:1, like using the hematocytometer. 10μl of this 
solution was transferred to the disposable slides specific for the machine and 
counted according the machine’s protocol. 
Another method used for counting the cells was using the Guava® easyCyte flow 
cytometer. The manufacturer’s instructions were followed for counting the cell 
number. The cells were diluted in the Guava ViaCount solution provided with the 
machine. The dilution was mentioned in the program while measuring the cells for 
the appropriate results. 
2.6.2 Therapy-induced senescence 
Lymphoma cells were seeded at a confluent density of approximately 5 x 105 cells 
per ml in a 6 well plate. Adriamycin was added to the medium to the final 
concentration of 0.05 μg/ml. Medium and feeder were changed after 3 days and cells 
were cultivated for 2 more days and harvested for further experiments. 
2.6.3 Chemical inhibitors treatment 
Lymphomas were treated with chemical inhibitors (14nM Semagacestat) and 
assayed after 24-48 hours.  
2.6.4 Induction of an inflammatory response 
Lymphomas were treated with a Lipopolysaccharide (LPS) concentration of 50ng/ml 
in serum-free medium for duration of 2 hours to induce an inflammatory response. 
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 2.7 Growth parameters and detection of cellular senescence 
2.7.1  Growth curve 
Adherent cells were trypsinized from original cell culture plates. 2 × 104 MEFs were 
plated onto 6-well plates. In case of suspension cells, such as lymphomas, 1-2 x 106 
cells were plated on fresh NIH 3T3 cell coated 6 well plates. Cell numbers were 
counted over a defined period and viable cell number was estimated by trypan blue 
exclusion or the Guava® easyCyte flow cytometer. 
2.7.2  Senescence Associated-β-galactosidase assay 
Suspension cells were collected on glass slides by cytospin. These cells temporarily 
adhere to the glass slides and can be fixed by carefully adding the fixation solution 
on top. Adherent cells were seeded in 6 or 12-well plates containing 5 mm round 
glass cover- slips and incubated under standard condition overnight to let the cells 
attach. Afterwards, medium was removed and cells were fixed in freshly prepared 
fixation solution. 
After 15 minutes incubation, fixation solution was removed and cells were washed 
twice in PBS. Staining solution was added and plates were transferred and 
incubated in a humidified atmosphere at 37°C for 16-20 hours. Cells were gently 
washed with PBS and mounted afterwards using Mowiol® 4-88.  
2.7.3  Cell cycle BrdU/ PI FACS analyses 
20 μM BrdU was added in the cell culture medium 2 hours before harvesting cells. 
Afterwards, cells were trypsinized, pelleted, washed with PBS. Cells were fixed by 
dropping 5 ml 80% ice-cold ethanol, while simultaneous vortexing and incubated in 
4°C for at least 24 hours. Furthermore, the cells were washed and resuspended in 
2M HCl and incubated at room temperature for 30 minutes. Post centrifugation, cells 
were treated with 0.1M Na-borate for 15 minutes and washed with PBST. Next, the 
cells were incubated with anti-BrdU- FITC antibody in the dark, overnight. Following 
day, cells were incubated with 100 μg/mL propidium iodide (in PBS) and analyzed by 
FACS.  
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 2.8 Immunoassays 
2.8.1 Immunoblotting (western blot) 
30~60 μg of protein samples were loaded in polyacrylamide gel and gel was run at 
80 volts (120 volts after proteins pass through the stacking gel) in 1x SDS running 
buffer. After electrophoresis, proteins were transferred to PVDF membrane using a 
semi-dry transfer chamber (BioRad). After the transfer was complete, the membrane 
was blocked with 5% milk in PBST for 1 h and then incubated with appropriately 
diluted primary antibody solution (5% BSA in PBST) at 4°C overnight. The blot was 
washed 3 times 10 minutes with PBST and incubated with appropriate secondary 
antibody for 1 h at room temperature. The blot was again washed with PBST and 
chemiluminescent peroxidase substrate was applied on the membrane. Images were 
visualized and taken by Intas Chemocam Imager or ChemiDoc MP Imaging System.  
2.8.2 Immunofluorescence (IF) 
Adherent cells were seeded in 6 or 12-well plates containing 5 mm round glass 
cover-slips and incubated under standard condition overnight to let the cells attach. 
Suspension cells were attached to the glass slides by cytospin. Cells were fixed with 
4% PFA for 15 minutes and washed 2 times with PBS. Then cells were 
permeabilized in 0.2% Triton X-100/PBS for 15 minutes and blocking with 1% 
BSA/PBS. After the incubation with primary antibody overnight (4°C), cells were 
washed 3 times 10 minutes with PBST, and subsequently incubated with 
fluorescence-labeled secondary antibody for 60 minutes in the absence of light. 
Cells were washed with PBST, mounted with ProLong™ Diamond Antifade 
Mountant or  and fluorescence was detected using Leica SPE fluorescent 
microscope or Keyence BZ-9000 fluorescence microscope. Slides were stored in the 
dark.  
2.8.3 Immunohistochemistry (IHC) 
Cells or tissue sections were fixed, permeabilized, blocked and incubated with 
primary antibody as described above (IF staining). On the next day, after washing 
with PBST, cells were stained with Dako REAL™ Detection System according to the 
manufacturer’s instruction. 
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2.8.4 Amyloid staining 
1.4mM stock solution of pFTAA, prepared in dH2O, was stored in -20°C. Working 
dilutions of 1:500 in PBS were used. The brain sections were prepared on glass 
slides using optimal cutting temperature compound (OCT compound). The sections 
were washed three times in 1x PBS to remove the cryoprotectant and incubated for 
30min in pFTAA staining solution at the working dilutions. These sections were again 
rinsed with 1x PBS and covered using the aqueous mounting agent Aquatex. These 
sections were analyzed the following day. 
2.8.5 Co-staining with pFTAA 
Staining with pFTAA was done after any other staining or assay that was combined 
with this staining (for e.g. Senescence Associated-β-galactosidase assay or 
immunostainings), as per their respective protocols. 
2.8.6 Quantification of Aβ by an electroluminescence linked immunosorbent 
assay system 
Intracellular and extracellular Aβ40 and Aβ42 concentrations in the control lymphoma 
cells were determined with an electroluminescence linked immunosorbent assay 
system (MSD assay) using the MSD 96- Well MULTI-SPOT® Human (4G8) Abeta 
Peptide Panel 1 V-plex Assay (MSD, Meso Scale Discovery). The Assay was 
performed using the instructor’s manual. 
 2.9 Quantitative real-time PCR 
For quantitative RT-PCR analyses (RQ-PCR), RNA was extracted with TRIzol 
(Invitrogen) and transcribed into cDNA using SuperScriptIII reverse transcriptase 
(Invitrogen) primed by oligo-dT according to manufacturer’s protocol. RQ-PCR 
analyses of candidate transcripts were conducted using commercially available 
primers (Applied Biosystems). Calculation of individual transcript expression levels 
relative to the expression of GAPDH as a housekeeping control mRNA has been 
described previously160. 
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RESULTS 
 1 Induction of senescence in Eμ-myc lymphomas using 
chemotherapy 
To study TIS, we used Eμ-myc-driven B-cell lymphomas as a model system, that 
overexpress the anti-apoptotic protein B-cell lymphoma 2 (Bcl2) via retroviral 
infection, referred to as control;bcl2 lymphomas from here on. Induction of DNA 
damage response using the chemotherapeutic drug Adriamycin (ADR, a.k.a. 
doxorubicin), resulted in TIS by evading apoptosis161,162 (Figure 5). Senescent cells 
exhibit different features such as senescence-associated-β-galactosidase (SA-β-gal) 
activity10, absence of the S phase detected by Bromodeoxyuridine (5-bromo-2'-
deoxyuridine)/Propidium Iodide (BrdU/PI) staining and up regulated protein 
expression of various markers of senescence detected by immunoblotting (Figure 6). 
SA-β-gal is a hydrolase enzyme mediates the hydrolysis of β-galactosidases to 
monosaccharides, which is a characteristic of senescent cells10. For visualization, a 
chromogenic substrate X-gal is utilized which results in the production of a blue dye 
precipitate163 (Figure 6A). BrdU, on the other hand, is used for detecting proliferation. 
It is incorporated into the DNA during the S phase of the cell cycle, since BrdU is an 
analog of thymidine. With an anti-BrdU antibody, cells that are actively replicating 
their DNA, thereby incorporated BrdU, can be detected. These cells are usually 
analyzed by flow cytometry, along with DNA dyes such as PI stain to observe cells in 
the various phases of cell cycle (Figure 6B). Senescent cells are mostly arrested in 
the G1 phase and S-phase cells disappear. As mentioned above, there are several 
proteins that have a defined role in senescence and therefore can be used as 
markers of cellular senescence. These include phosphorylation of p53- serine 15, 
p21 and trimethylation of H3K9 (Figure 6C). 
Observing a combination of all these senescence features is used in this thesis to 
confirm cellular senescence. 
 
RESULTS 
 51 
 
Figure 5: Therapy-induced senescence in Eμ-myc-driven B-cell lymphomas. 
Senescence induction using a chemotherapeutic agent such as ADR or CTX induce 
DNA damage, resulting in TIS. TIS is controlled by  p53 and/or p16INK4a. These 
anticancer agents cause activation of p53 independent of ARF, as loss of function 
mutation or loss of p53 or INK4a leads to senescence defect, while deficiency of 
ARF alone is unable to disrupt senescence. Therefore, induction of senescence by a 
DNA damaging procedure leads to an upregulation of p53 and p16INK4a, probably via 
a common mechanism. Anti-apoptotic gene Bcl2 prevents the cells from undergoing 
apoptosis in response to DNA damage and bypasses the cells into senescence. 
Figure adapted from Schmitt et al. 200253. 
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Figure 6: Markers of senescence. (A) The increased lysosomal activity that is 
characteristic of a senescent cell, observed by SA-β-gal assay. (B) BrdU/PI staining, 
where the S phase of the cell cycle disappeared, observed 5 days after treatment. 
(C) The expression levels of senescence markers were observed by immunoblotting.  
A
B
C
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 2 Senescence presents with features reminiscent of Alzheimer 
Disease 
 2.1 Therapy-induced senescence is associated with AD genes 
2.1.1 Affymetrix data revealed an upregulation of AD genes in TIS capable 
cells 
Affymetrix Mouse Genome 430 2.0 Array using 15 matched pair control;bcl2 
lymphomas was performed by colleagues from the lab. The enriched pathways in 
TIS lymphomas were determined. Upon screening the KEGG pathway database, 
genes of the AD pathway were enriched in TIS lymphomas. AD pathway according 
to the KEGG database presents with genes that contribute to the pathology of AD. 
This database was used to define a set of genes- termed collectively as the “AD 
machinery or AD genes”. 
By utilizing the Bioconductor pathview on R, the individual AD genes that have an 
altered expression after TIS compared to their untreated control;bcl2 lymphoma 
matched pair, were depicted (Figure 7A). When senescence was induced in 
control;bcl2 lymphomas after ADR treatment, many AD genes were up regulated 
(represented in red) and some were down regulated (represented in green). Some of 
the genes of the AD pathway appeared to be unchanged post TIS. 
On the other hand, lymphomas which are incapable of undergoing senescence, such 
as the Suv39h1-/-;bcl2 lymphomas, did not show the same degree of change in the 
expression of AD genes after treatment (Figure 7B). However, the threshold of 
detection is a limitation of this analysis. There is a saturation point to detect the level 
of alteration in expression. Beyond a certain level of up regulation or down 
regulation, change in color intensity cannot be observed. Therefore, it is possible 
that if there is a certain gene that appears altered in both control and Suv39h1-/-;bcl2 
lymphomas, the degree of alteration could vary compared to the other. Further 
quantitative analyses were carried out to understand these differences in detail. 
Additionally, it is possible that some players of AD could be acting upstream or 
downstream of the “senescence pathway”. Hence, in the case of senescence 
capable or incapable lymphomas, some of the AD genes could still be involved in the 
DDR and would be equally altered in both the cases. 
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Figure 7: KEGG pathway map of Alzheimer’s disease representing the up or 
down regulation of AD genes UT vs ADR treated lymphomas. (A) Control;bcl2 
lymphomas TIS/UT gene expression of the AD machinery. (B) Senescence 
incapable Suv39h1-/-;bcl2 lymphomas ADR/UT gene expression of the AD 
machinery. The up regulation is depicted by red tiles and down regulation is depicted 
by green tiles. 
To determine if there are any overlapping features between TIS and AD, the AD 
gene set defined from the gene expression data set from the 15 match paired 
control;bcl2 lymphomas and 5 match paired Suv39h1-/-;bcl2 lymphomas was used 
for gene set enrichment analysis (GSEA) (Figure 8). An enrichment of the AD genes 
in ADR treated lymphomas, normalized to the corresponding untreated cells, was 
observed in the GSEA plot. The AD genes were enriched in TIS control;bcl2 
lymphomas (Figure 8A, left) but not in the ADR treated senescence incapable 
Suv39h1-/-;bcl2 lymphomas (Figure 8A, right). The heat map represents the 
expression pattern of these individual genes in the individual matched pair 
control;bcl2 lymphomas (Figure 8B, left). The AD related genes in the control;bcl2 
lymphomas cluster into two distinct groups, up regulated or down regulated AD 
genes post-treatment. However, in case of the senescence incapable Suv39h1-/-
;bcl2 lymphomas, ADR treatment did not result in a clear pattern of up or down 
regulation of these genes (Figure 8B, right).  
Since the upregulated AD genes were enriched in TIS capable lymphomas but not in 
senescence incapable lymphomas, this suggests a biological overlap between TIS 
and AD. Moreover, it is intriguing that TIS in lymphomas has an impact on the 
expression of AD genes, since there is no known function of some of these genes, 
e.g. APP, in the context of lymphomas or TIS. 
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Figure 8: AD gene distribution in Eμ-myc-driven B-cell lymphomas UT (native) 
vs TIS. Genes involved in Alzheimer’s disease were significantly altered in TIS 
control lymphomas. (A) The GSEA of Alzheimer’s disease targets shows their 
enrichment (represented by Normalized enrichment score, NES) in senescence 
capable control;bcl2 lymphomas (n=15) but not in senescence incapable Suv39h1-/-
;bcl2 lymphomas (n=5) in the gene expression plot of UT vs ADR treated setting. (B) 
Heat maps show individual gene expression of individual lymphomas, UT vs ADR 
treated. 
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Table 1: AD genes. Alzheimers related genes derived from the KEGG pathway, 
which are up regulated in TIS control;bcl2 lymphomas. 
 
 
Up regulated AD genes in TIS 
 
Psen1 
APP 
Psen2 
LRP1 
Calm1 
Ncstn 
LPL 
Apoe 
Gsk3b 
Adam10 
Ece1 
Sort1 
Psenen 
Aph1a 
Casp7 
IL6 
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2.1.2 Taqman® based real time PCR validation of Affymetrix data 
All the above-mentioned data analysis is representative of the high throughput data 
from the microarray affymetrix dataset. Therefore, as a validation, the expression of 
the up regulated genes involved in KEGG Alzheimer’s disease gene set were 
analyzed using Taqman® based real time PCR (RQ-PCR). Changes in the 
expression of these genes were observed 5 days post ADR-treatment. The AD 
genes with significant up regulation in the heat map (Figure 7A) exhibited similar 
trends via RQ-PCR (Figure 9B). Interestingly, when a set of Suv39h1-/-;bcl2 
lymphomas were analyzed for change in expression of the same genes after 
treatment, their expression levels, in most cases, were much lower as compared to 
the control;bcl2 lymphomas (Figure 9B). This confirmed that there is indeed more 
relevance of the AD in the context of senescence. 
 2.2 Proteotoxicity and SASP may be the link between TIS and AD 
Proteotoxic stress has been reported in both AD and senescence70,159. Therefore, to 
determine whether AD machinery is only involved when protetoxic stress correlates 
with senescence, senescence was induced by rapamycin (an mTOR inhibitor)164. 
Rapamycin-induced senescence is accompanied by autophagy induction but lacks a 
SASP response. As a result, it is not associated with proteotoxicity-driven ER 
stress70. Treatment with rapamycin induced senescence to an extent which was 
comparable to TIS upon ADR treatment70 (Figure 9A). Interestingly, in this setting 
the AD genes were unaffected, suggesting their association with proteotoxic stress 
(Figure 9B). This result further led us to pursue this project, to understand the link 
between senescence and AD, a disease with defective proteostasis. 
Additionally, as discussed above, SASP is a NF-κB-driven phenomenon58. SASP 
leads to an increased protein production in senescence, which requires for an 
elevated autophagy to degrade the misfolded SASP components. Therefore, to 
understand if SASP related proteotoxicity is the link between senescence and the 
AD machinery, control;bcl2 lymphomas were stably transduced with NF-κB super-
repressor, IκBαΔN165. These lymphomas maintain their ability to undergo TIS, in 
vitro, in response to ADR treatment160. Post-TIS, they have been shown to express 
proteins only slightly above the baseline of the non-senescent control;bcl2 
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lymphomas70. Likewise, senescent NF-κB-repressed cells express SASP cytokines 
at a lower level160. On analyzing expression of AD genes in the ADR-induced TIS of 
NF-κB-repressed cells, the AD genes were also expressed at a lower level, when 
compared to the ADR induced TIS of control;bcl2 lymphomas (Figure 9B). 
Confirmingly, this suggests that reduced SASP cytokine production also leads to a 
lower expression of the AD genes. 
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Figure 9: AD gene expression in various TIS settings (A) SA-β-gal confirms 
senescence in different settings and treatments. (B) RQ-PCR analysis of the 
indicated AD genes that are up regulated, as in Figure 8. The relative expression 
levels are normalized to the control cells carrying the vector, that are comparable 
throughout all datasets. Fold change of the relative expression levels, compared to 
the UT matched pair lymphoma, are indicated in the histogram. The relative 
expression levels of the UT lymphoma was set to 1 (indicated by the red line). IL6 
represents a SASP factor, which is a secreted NF-κB target. All histogram bars 
indicate mean values + standard deviation. 
Therefore, from these experiments we infer that there is an involvement of AD genes 
in the context of senescence. These genes were up regulated when TIS was 
induced in control;bcl2 lymphomas by ADR but not by Rapamycin treatment. This 
suggests that the role of AD genes in the context of TIS could be the underlying 
proteotoxic stress. Moreover, TIS in the NF-κB-repressed cells, thereby the SASP-
repressed cells, also resulted in lower expression of the AD genes as compared to 
the controls. However, not all the AD genes were completely repressed in TIS of the 
NF-κB-repressed cells, e.g. LPL, LRP1, APP, and SORT1, but their expression was, 
for the most part, many folds lower in comparison. This could be due to a repressed 
but not completely absent SASP in these cells, resulting in some proteotoxic stress. 
Besides, these genes could also have other unidentified functions in senescence. 
Hence, it can be concluded that SASP, being a major contributor of proteotoxicity in 
a senescent cell, could possibly be the common denominator between AD and TIS. 
 2.3 APP and Psen1 are not induced as an inflammatory response 
It was observed that AD machinery was only up regulated in the case of TIS after 
ADR treatment, which includes SASP (Figure 9). SASP involves secretion of 
inflammatory factors that might facilitate induction of AD machinery in TIS 
lymphomas, either through an inflammation specific response or a senescence 
specific response.  
To determine this, lymphomas were treated with lipopolysaccharide (LPS) to induce 
an inflammatory response. LPS is a large molecule, consisting of a lipid and a 
polysaccharide. It acts as an endotoxin since it can bind to the 
CD14/TLR4/MD2 receptor complex and stimulate cells such as B cells, 
macrophages, etc., to secrete pro-inflammatory cytokines166–168. Induction of an 
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inflammatory response was confirmed by analyzing the change in the expression 
levels of IL6 and IL1a by RQ-PCR (Figure 10). Even though there was a significant 
change in the mRNA expression levels of IL6 and IL1a, mRNA expression levels of 
the representative players of AD- APP and Psen1, were not affected. This suggests 
that the link between AD machinery and senescence is SASP and not inflammation, 
per se. 
 
 
 
 
 
 
Figure 10: Inflammatory response and AD. Control;bcl2 lymphomas were treated 
with LPS in order to induce an inflammatory response. This was confirmed by the 
increase in the expression levels of IL6 and IL1a, which are also secreted targets of 
NF-κB. The expression levels of a few representative targets of the AD machinery, 
APP and PSEN1 were also observed. The relative expression levels of the UT 
lymphoma was set to 1 (indicated by the red line). All histogram bars indicate mean 
values + standard deviation. (n=4) 
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 2.4 Oncogene-induced senescence does not involve AD gene 
upregulation 
Activation of the alzheimers genes after TIS in control;bcl2 lymphomas suggested 
that there is probably some unearthed role of this machinery in senescent cells. But 
whether the involvement of the AD machinery was restricted to TIS or if could also 
be a component of other forms of senenscence was not yet clear. Thus, to address 
this, OIS which is another major senescence type involved in tumor progression, 
was explored. 
Senescence was induced in MEFs by over expressing RasG12V mutant in the wild 
type cells. These cells undergo OIS due to the DNA damage. After RasG12V was 
successfully induced in MEFs, the cells typically show senescence markers within 10 
days (Figure 11A), following which the expression of the AD genes were analyzed. 
Interestingly, this type of senescence did not result in the up regulation of AD genes 
(Figure 11B), suggesting that this machinery is not involved in all types of 
senescence. 
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Figure 11: AD gene expression in OIS. (A) OIS was induced in MEFs by 
overexpression of the RasG12V oncogene. Senescence was confirmed 10 days 
after infection, by SA-β-gal. (B) The expression analysis of the same subset of the 
AD genes as in TIS was analyzed. The relative expression levels of the WT MEFs 
was set to 1 (indicated by the red line). All histogram bars indicate mean values + 
standard deviation. (n=4) 
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 3 AD model systems exhibit features of senescence 
 3.1 Brain of APPPS1+/- transgenic mice indicate co-occurrence of 
senescence and Aβ plaques 
Recent reports strongly suggest a role for senescence in the etiology of AD169. The 
underlying mechanism however is not well understood. Here, we used different AD 
model systems and investigated various features of senescence associated with 
them. 
To understand the association between senescence and AD, from an AD viewpoint, 
the brains of an AD mouse model were analyzed. These mice are double transgenic 
for APP and Psen1 (APPPS1+/-). They start  to develop AD characteristics, such as 
Aβ plaques, from as early as 2 months of age. Cognitively, they exhibit impairment in 
behavorial assessments such as memory tests, by the age of 8 months170. The 
presence of Aβ plaques in their brains was visualized by the pFTAA dye (Figure 
12A), because pFTAA dye has an affinity to bind to the conformational structure of 
these plaques171. 
As expected, the older (330 days) transgenic mice developed a prominent plaque 
phenotype when compared to the younger (69 days) transgenic mice (Figure 12A). 
This phenotype is gender independent as equal numbers of female and male mice 
were analyzed with similar results. Moreover, the age-matched wild type C57BL/6 
control mice did not show any Aβ plaques in the brain sections of neither younger 
nor older age groups. These results confirmed the involvement of APP and Psen1 in 
plaque generation. 
Interestingly, SA-β-gal staining of the same brain sections demonstrated that the 
older transgenic mice present with a higher number of prominent blue cell clusters, 
as compared to younger mice. The age matched wild type mice brains did not show 
any significant staining (Figure 12B). This indicates that in APPPS1+/- transgenic 
mice, increasing age not only results in higher number of Aβ plaques but also 
causes higher level of senescence in their brains. The young transgenic mice 
reiterated this observation with an exhibition of much lower number of plaques 
correlating with lower level of senescence. Moreover, the Aβ plaques and senescent 
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cells exhibited co-localization, with senescent cells largely present in the peripheral 
regions of the plaques (Figure 12C). This suggests that APP and Psen1 are not only 
relevant for plaque generation, but also have a direct or indirect involvement in the 
senescence induction. 
More number of senescent cell clusters was found to be present in the brain of 
younger transgenic mice as compared to the plaques, suggesting a possibility that 
senescence precedes plaque formation. Taken together, these results provide 
strong circumstantial evidence for the involvement of senescence in AD related 
plaque formation.  
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Figure 12: Correlation between senescence and Aβ plaque. Brain sections of 
APPPS1+/- transgenic mice, with age groups of 69 days (n=4) and 330 days (n=3) 
were double stained for extracellular Aβ plaques and senescence. Same number of 
age matched C57BL/6 wildtype (WT) mice were used as controls. (A) Aβ plaques in 
the brains of mice differing in age or genotype were analyzed. Higher numbers of 
plaques were observed in 330 days old transgenic mice, compared to the 69 days 
old mice. The WT mice showed no detectable plaques up to 330 days of age. (B) 
These images describe senescence in the brains of the mice. The number of 
senescent cell clusters observed in these brain sections was directly proportional to 
the Aβ plaques. (C) Co-localization of images (A) and (B) revealed that senescent 
cells were present around the Aβ plaques. 
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 3.2 Aβ plaques were not detected in TIS lymph nodes 
We observed that TIS in control;bcl2 lymphomas show up regulation of APP 
transcripts, quantified by RQ-PCR. This led us to the next question, whether TIS 
lymph nodes present with Aβ plaques, as in the brain of APPPS1+/- mice. 
To achieve this, mice bearing lymph nodes were treated with cyclophosphamide 
(CTX). TIS was confirmed 7 days post treatment, by SA-β-gal assay of lymph node 
sections. These sections were co-stained with Aβ antibody for detecting Aβ plaques 
by immunohistochemistry. It was observed that in these senescent lymph nodes, Aβ 
plaques were not formed (Figure 13). Similarly, no plaques were observed when 
pFTAA dye was used for the detection of Aβ plaques (data not shown). 
This implies there are no Aβ plaques formed in the lymph nodes of control;bcl2 
mouse models. It is possible that lymphoma cells do not release Aβ to form plaques. 
Alternative explanations could be that 7 days is insufficient to form plaques in the 
lymph node or may be the Aβ that is released by the cell is washed away due to a 
flow through of lymph through the lymph node. 
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Figure 13: Aβ plaque detection in lymph node sections post TIS. Lymph node 
sections from pairs of mice (n=4) transplanted with the same lymphomas. One 
mouse was exposed to treatment with cyclophosphamide (CTX) whereas the other 
mouse was used as a control (UT). The sections were double stained with SA-β-gal 
(blue) followed by IHC for Aβ plaques (red). 
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 3.3 APP contributes to ER stress and autophagy along with other 
markers of senescence  
As previously mentioned, there are certain proteins, including p53 and p16, which 
are strong mediators of cellular senescence. These proteins have been 
demonstrated to be indispensable in senescence, as their absence potentially allows 
cells to escape senescence32,172,173.  
Swedish mutation of APP is one of the well-known genetic mutations leading to 
EAOD (FAD)174. Many mouse models carrying this mutation are used to study 
genetic forms of AD. Interestingly, overexpression of Swedish mutation of APP in a 
neuroblastoma cell line SH-SY5Y, a cell line model for AD, resulted in an increased 
expression of many of these senescence marker genes (Figure 14): phosphorylation 
of p53, induction of p21, increased tri-methylation of H3K9, etc. Furthermore, it was 
observed that the overexpression of APP also induced ER stress (detected by the 
increased p62 (or p62/SQSTM1) expression) as well as a burden on the autophagic-
lysosomal machinery (detected by the increased cleavage of MAP1-LC3-I-isoform to 
MAP1-LC3-II-isoform). This reiterated the findings of Yang and colleagues, where 
they described that in an APP transgenic mouse model there is an accumulation of 
undigested autophagy substrates like p62 and MAP1-LC3-II-isoform, thereby hinting 
towards compromised autophagic-lysosomal machinery175.  
Although over expressing APP in SH-SY5Y cells led to an up regulated expression 
of many proteins involved in senescence induction, it was not sufficient to induce 
senescence in this cell line (observed by growth curve and SA-β-gal assay, data not 
shown). This could be because these cell lines are immortal and can overcome the 
stresses caused by over expression of these proteins. 
Therefore, from these results we can infer that in addition to AD, APP also 
contributes towards selective features of senescence, such as up regulation of 
proteins that are either regulators of senescence or downstream to them. This 
argues for a potential role for APP in senescence biology.  
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Figure 14: Consequences of APP overexpression on markers of senescence  
Swedish mutation of APP was overexpressed in SH-SY5Y cell line. This led to an 
induction of many markers of senescence, depicted by immunoblot analysis. Tubulin 
was used as a loading control (n=3).  
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 4 APP over expression does not make a cell susceptible towards 
TIS 
Figure 14 demonstrated that the neuroblastoma cell lines over expressing APP led 
to an up regulation of the senescence markers, indicating a possible pre-existing 
senescence burden in the APP overexpressing neuroblastoma cells. Since, this 
burden was not sufficient to induce senescence in these cells, therefore, the next 
question that arises is whether it predisposes them towards TIS. 
To explore this, the SH-SY5Y cells (parental and Swedish APP) were treated with 
ADR, similar to control;bcl2 lymphomas. A change in cellular morphology was 
observed, as the cells appeared more flattened. However, about 60% of the viable 
cell population was rendered senescent 5 days post treatment, irrespective of the 
APP status, confirmed by SA-β-gal staining (Figure 15A). Likewise, there was a 
sharp increase of G1 phase cells in treated cells (66.1%) as compared with the 
untreated cells (48.3%) but not all cells were arrested as indicated by S-phase 
fractions with positive BrdU staining (Figure 15B). This difference might be due to 
suboptimal levels of ADR dosage or treatment time.  
When the growth of these cells was monitored (Figure 15C), we observed that the 
APP overexpressing SH-SY5Y cells grow at a slower rate as compared to the 
parental cells. This could be due to the increased proteotoxic or other burdens of 
these cells. Post treatment, the viable cell population was reduced to half after 3 
days (Figure 15C, lower box). This revealed that initially ADR treatment induced 
death of around 50% of the cell population. The remaining cells were partly 
senescent and partly non-senescent. The non-senescent cells appear to proliferate 
albeit at a much slower rate as compared to the untreated cells. Both the parental 
and the Swedish APP variants of SH-SY5Y cells exhibited similar outcomes. Varying 
concentrations of ADR (10 or 100 fold) were also used to induce senescence in 
these cell lines but they proved to be highly toxic (data not shown). 
In conclusion, on one hand, using the neuroblastoma cell line as a model system of 
AD exhibited a mechanistic correlation between APP and some markers of 
senescence. But on the other hand, they don’t seem to be an appropriate model 
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system of TIS, due to their inability to undergo TIS homogenously via the standard 
treatment applications. 
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Figure 15: Inducing TIS in neuroblastoma cell line SH-SY5Y. (A) A subset of the 
cell population turned blue via SA-β-gal assay. (B) BrdU/PI staining displayed that 
some cells are still in the S phase of the cell cycle. (C) Growth curve analysis of the 
cells (n=3) as in (A). The lower box displays the change in viability of the ADR 
treated cell lines with a smaller scale for y-axis for a closer look. 
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 5 APP and PSEN1 in senescence 
 5.1 APP and PSEN1 depletion does not impact the senescing 
ability of a cell 
To better understand the role of the underlying molecular mechanisms of AD genes 
in the context of senescence, knockdown loss of function approach was used. APP 
and PSEN1 were selected as targets because these are two of the most commonly 
altered genes in the case of EOAD. 
A construct expressing small hairpin RNAs (shRNA) against these genes was 
introduced in the control lymphomas to induce their knockdowns. Five sequences of 
shRNAs for each of the genes were tested for their ability to knockdown gene 
expression, monitored by real-time PCR (data not shown). The shRNAs that 
demonstrated the most significant knockdown levels were therefore selected for 
further experiments. Sufficient levels of knockdown were obtained for both gene 
players. APP and PSEN1 expression levels were knocked down to less than 30% 
and 1% of endogenous levels, respectively (Figure 16A). 
These APP and Psen1 depleted cells were then treated with ADR to induce TIS. SA-
β-gal and BrdU/PI staining confirmed marginally reduced senescence (Figure 16B) 
that did not achieve statistical significance. Thus, we can conclude that APP and 
PSEN1 do not influence the cell’s ability to undergo TIS. 
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Figure 16: Senescence induction independent of APP and Psen1. (A) APP and 
PSEN1, most relevant players of Alzheimer’s disease, were knocked down in 
control;bcl2 lymphomas (n=3) using shRNAs as shown here with their respective 
mRNA expression levels. (B) Knockdown of APP and PSEN1 did not affect the 
ability of the cells to undergo senescence. This was preliminarily confirmed by SA-β-
gal (left), as well as by BrdU/PI staining (right).   
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 5.2 APP depletion reduces ER stress associated with senescence 
In the context of neuroblastoma cell lines, APP overexpression induced ER stress 
and autophagic lysosomal burden as shown in Figure 14. This suggests for a role of 
APP in these processes. To determine whether APP contributes to senescence 
associated ER stress and the autophagic-lysosomal burden in control;bcl2 
lymphomas, along with other senescence features, knockdown loss of function 
approach was used.  
As observed in Figure 16B, both the control and shAPP-transduced lymphomas 
exhibited TIS. Subsequently, their expression patterns were compared by 
immunoblotting. A reduced protein expression level of APP was observed (Figure 
17) in the untreated shAPP-transduced lymphomas. But, after TIS induction, the 
expression of APP was similarly up regulated as in the control-transduced 
lymphomas.  
Importantly, a dynamic pattern of TIS associated expression of various proteins was 
observed (Figure 17). The expression level of p21 was up regulated in the untreated 
shAPP-transduced lymphomas, whereas H3K9me3 expression was down regulated, 
as compared to the untreated control-transduced lymphomas. However, p21 
expression levels were further up regulated in shAPP-transduced lymphomas post 
TIS. On the other hand, the H3K9me3 levels were up regulated similar to the control-
transduced lymphomas, post TIS. Phospho-p53 expression appeared unaffected in 
these lymphomas.  
In terms of ER-stress, there was a decrease in p62 expression when APP was 
knocked down. Post TIS, senescence related ER stress remained significantly lower, 
thus confirming the contribution of APP towards this phenomenon (Figure 17). The 
autophagic-lysosomal burden, detected by the expression levels of MAP1-LC3-II-
isoform, was also reduced after a knocked down APP expression. However, the 
conversion of MAP1-LC3-I-isoform (depicted by the upper LC3 band) to MAP1-LC3-
II-isoform (depicted by the lower LC3 band) was restored to similar levels post-TIS 
as compared to the control-transduced lymphomas. This could also be due to the 
incomplete knockdown of APP, which suggests that even low levels of APP are 
sufficient to induce autophagic burden. Alternatively, SASP and other senescence 
related factors could also be responsible for most of the burden on the autophagic-
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lysosomal machinery. Absolute conclusions cannot be made, as there was an 
incomplete knockdown of APP. Moreover, post-TIS, the APP expression levels were 
induced again, possibly enough to partly carry out its functions. Using an APP 
knockout system may lead to more conclusive answers. 
This suggested that APP, albeit only in part, does support TIS and establishes TIS 
as a complex process involving concerted regulation by several proteins which need 
to be further studied. 
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Figure 17: Correlating APP with senescence markers. This immunoblot 
demonstrates the expression of APP in untreated and TIS, control-transduced 
lymphomas (n=3) and shAPP-transduced lymphomas. The correlation between APP 
and the expression of markers of senescence was determined by comparing their 
protein expression patterns. The impact of knocking down APP on ER-stress and 
autophagic-lysosomal burden was depicted by analyzing the expression levels of 
markers such as p62, MAP1-LC3-I-isoform (upper band) to MAP1-LC3-II-isoform 
(lower band) conversion. Elevated autophagic flux, and activation of the lysosomal 
vacuolar type H+-ATPase was observed by vATPase A1 levels. The expressions of 
all the proteins are normalized using β-actin.   
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 6 Inhibition of APP processing using a Gamma-secretase inhibitor 
We observed that APP overexpression burdens the cellular system with proteotoxic 
stress, whereas, depleting the system of APP reduces this stress. To narrow down 
the mechanism by which APP strains the cells, especially in TIS, APP processing 
was specifically targeted. Figure 4 illustrates various enzymes that are responsible 
for cleaving APP into smaller peptides. 
γ-secretase, along with β-secretase or α-secretase, are key enzymes involved in the 
processing of APP. γ-secretase cleavage in combination with β-secretase forms the 
Aβ peptide and plaques- the major culprit behind the AD pathology176–181. Many γ-
secretase inhibitors were or are in clinical trials for improving the prognosis of AD. 
Therefore, the first question that intrigued us was whether APP-cleavage, specifically 
via the γ-secretase pathway, contributes towards senescence and inflicts a 
proteolytic burden in a cell via its processed product, Aβ. 
The γ-secretase inhibitor Semagacestat was chosen for further studies because its 
effectiveness on the γ-secretase inhibition has been confirmed in vitro182. As 
previously mentioned, although the drug had advanced to the phase III of the AD 
clinical trials for showing the potential to reduce Aβ levels in the plasma, it failed to 
reduce Aβ in the cerebrospinal fluid and brought about many other side effects127–
129. 
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 6.1 Promising senolytic effects of Gamma-secretase inhibition 
To begin with, the effect of γ-secretase inhibition on the viability of the TIS 
control;bcl2 lymphomas was determined. The effect of γ-secretase inhibition on the 
viability of the untreated, proliferating control;bcl2 lymphomas was used as a control. 
TIS was induced in control;bcl2 lymphomas by ADR treatment. On day 5 after 
senescence induction, Semagacestat was added to inhibit γ-secretase in TIS as well 
as the non-treated/non-senescent control;bcl2 lymphomas, and results were 
analyzed after 2 days. Treating the non-senescent lymphomas with Semagacestat 
did not affect their viability, that is, the cells continued growing exponentially (Figure 
18A). But in case of TIS, the viability of the cells was reduced post inhibition (Figure 
18B). This suggests that the γ-secretase inhibitors like Semagacestat might have 
senolytic properties. However, the exact mechanism of these effects in senescent 
cells needs to be further investigated. 
 
Figure 18: Senolytic effects of Semagacestat. Control lymphomas were 
sequentially treated- with ADR to induce senescence, followed by Semagacestat, 
and the growth curve was plotted to analyze the effects on viability. (A) In non-
senescent control;bcl2 lymphomas, Semagacestat did not affect the viability of the 
cells. (B) In TIS control;bcl2 lymphomas, inhibiting γ-secretase enzyme led to 
expedited cell death (n=4). 
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 6.2 Gamma-secretase inhibition does not demonstrate disruption 
of the APP processing in control;bcl2 lymphomas 
Disruption of APP processing via γ-secretase was aimed to demonstrate the impact 
of restricted Aβ production in non-senescent as well as senescent lymphomas. Since 
knocking down APP resulted in reduction of senescence related ER stress, targeting 
γ-secretase enzyme was an approach to decipher the mechanism by which APP 
contributes to this stress. 
As mentioned above, γ-secretase, depending on the combination with other 
enzymes (β-secretase or α-secretase) results in the formation of different peptides, 
such as APP intracellular domain (AICD) (~7 kDa), p3 (~2.5 kDa) and Aβ (~4.5 kDa), 
which are secreted in the extracellular environment or are transported to the nucleus 
(Figure 4). γ-secretase cleaves towards the c-terminal of APP, therefore, when γ-
secretase is blocked, the CTFs remain intracellular and membrane bound. We 
analyzed for the expression of APP and APP-CTFs, via immunoblot analysis, using 
APP-CTF specific antibody. We observed that the inhibition of the γ-secretase in 
lymphomas did not result in an accumulation of the APP-CTFs in either UT or TIS 
setting (Figure 19A). Proteolytic processing of APP was also determined by 
immunofluorescence staining, using the same APP-CTF specific antibody. Although 
no significant differences were observed by immunoblot analysis, 
immunofluorescence staining showed more sensitivity in detecting significant 
changes in the cumulative expression levels of APP and its CTFs after γ-secretase 
inhibition (Figure 19B). 
From this we can conclude that in TIS of control;bcl2 lymphomas, there is an 
increase in the expression levels of APP. The inhibition of its processing further led 
to the accumulation of its CTFs within the cell. Although the change in their 
expression levels was out of scope to be detected by immunoblotting, detection by 
immunofluorescence demonstrated an increase in cumulative accumulation of APP 
and APP-CTFs.  
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Figure 19: γ-secretase inhibition in a control;bcl2 lymphomas. (A) Cell lysates 
of control;bcl2 lymphoma cells (n=4) treated with ADR and Semagacestat were 
analyzed by immunoblot to visualize APP processing. (B) The distribution of the APP 
full-length protein and C-terminal peptides was observed by immunofluorescence.  
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 6.3 Gamma-secretase inhibition impedes APP processing in the 
APP overexpressing neuroblastoma cell line 
Since we were unable to observe a conclusive effect of Semagacestat on APP 
processing in control;bcl2 lymphomas by immunoblotting (Figure 19A), the 
experiment was duplicated in the SH-SY5Y cell lines. This was done to validate and 
confirm the function of Semagacestat as an inhibitor of APP processing at the 
selected concentration. 
The SH-SY5Y cell lines, parental and APP overexpressing, were treated with 
Semagacestat for 2 days. It did not have any effect on the viability of the cell line in 
either setting (data not shown). The effect of γ-secretase inhibition on APP 
processing was observed by immunoblot analysis. In the case of parental SH-SY5Y 
cell line, we observed no significant accumulation of APP-CTFs post γ-secretase 
inhibition. It is possible that the levels of these peptides are below the threshold of 
detectability by these techniques (Figure 20A). However, in APP overexpressing SH-
SY5Y cell line, there was a significant accumulation of the APP-CTFs, thus 
validating the inhibition of γ-secretase by Semagacestat. Additionally, the effect of γ-
secretase inhibition on APP and its CTFs was also observed by 
immunofluorescence, using the same antibody as in the immunoblot, which is 
specific for the CTF of APP (Figure 20B). The antibody generates a cumulative 
fluorescence signal for full length APP, as well as its intracellular CTF. Like 
immunoblotting, the effect of γ-secretase inhibition in the APP overexpressing SH-
SY5Y cell line was more pronounced. 
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Figure 20: γ -secretase inhibition in a Neuroblastoma cell line. (A) The 
accumulation of APP CTFs were observed only in case of APP overexpressing SH-
SY5Y cell line (n=3), by immunoblotting. The parental cell lines did not demonstrate 
an accumulation of the CTFs. (B) The distribution of the proteins and peptides were 
observed by immunofluorescence, which showed similar results as the immunoblot, 
for APP and its intracellular CTFs.  
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Hence, we could confirm the inhibition of the γ-secretase enzyme, which further 
impedes the final cleavage of APP and leads to the accumulation of its CTFs. 
Although γ-secretase was inhibited in both the parental as well as the APP over 
expressing SH-SY5Y cells, its effects were visible in case of APP over expressing 
cell line only. This suggests a possibility that the endogenous expression levels of 
APP are critical for visualization by routine techniques. This could also be an 
explanation why the effects of γ-secretase inhibition was not visible in control;bcl2 
lymphomas. 
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 6.4 Gamma-secretase inhibition in the control;bcl2 lymphomas 
does not affect TIS associated proteotoxicity nor other 
senescence markers 
Although no effect of γ-secretase inhibition on APP processing was observed in the 
control;bcl2 lymphomas, we further pursued to understand its effect on other 
markers of senescence and proteotoxicity. This was done because we observed a 
senolytic potential of Semagacestat in control;bcl2 lymphomas which suggested 
some effect by some unknown mechanisms. Moreover, the inability to confirm the 
effect of the drug on APP processing by immunoblotting, possibly due to low 
endogenous APP levels, could be a drawback of the model system. 
After γ-secretase inhibition, the senescent cells maintained a positive SA-β-gal 
staining, with a slight decrease in the percentage of senescent cells (Figure 21A). 
Immunoblot analysis revealed that the inhibition of γ-secretase did not affect the 
observed markers of senescence or proteotoxicity (Figure 21B). Therefore, in 
conclusion, blocking the processing of APP via the γ-secretase enzyme in 
control;bcl2 lymphomas did not have an impact on TIS. Moreover, the APP products 
formed by γ-secretase cleavage do not significantly contribute to proteotoxic stress 
associated with TIS. This implies that proteotoxic stress exhibited in TIS by APP is 
Aβ-independent. 
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Figure 21: Mechanistic implications of γ-secretase inhibiton on senescence 
markers in control;bcl2 lymphomas. (n=4)  (A) Effect of γ-secretase inhibition of 
senescent cells was observed preliminarily by SA-β -gal assay. (B) Immunoblot 
analysis indicating the effect on markers of senescence when gamma-secretase was 
inhibited. β-actin was used as a loading control.  
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 6.5 Gamma-secretase inhibition in the neuroblastoma cell line 
marginally affects proteotoxicity as well as other senescence 
markers 
Subsequently, the next step was to investigate whether blocking the cleavage of 
APP via γ-secretase inhibition in SH-SY5Y cells, would impact the expression of 
senescence and proteotoxicity markers. Since APP overexpression induced these 
stresses in the cell line, we were interested to know if blocking its processing would 
alleviate them. 
The expression of majority of the senescence markers appeared to be unaffected 
when the γ-secretase enzyme was inhibited in case of the SH-SY5Y parental as well 
as APP overexpressing cell line (Figure 22). There was a slight decrease in the 
expression of p21 and MAP1-LC3-II isoform post γ-secretase inhibition in both 
settings. This suggests inhibiting the γ-secretase marginally decreased that 
autophagic-lysosomal burden, possibly caused by the processing of APP. This also 
reiterates the observation from knocking down APP in control;bcl2 lymphomas 
(Figure 17), suggesting APP partly contributes to the autophagic-lysosomal burden 
via γ-secretase mediated processing. On the other hand, pattern of p21 expression 
cannot be explained. This is because knocking down APP increased p21 expression 
in control;bcl2 lymphomas but inhibiting γ-secretase led to a decrease in its 
expression both parental and APP overexpressing SH-SY5Y cell lines. 
In conclusion, it could be predicted that Aβ and other by-products of γ-secretase 
cleavage do not exclusively account for the role of APP in proteotoxicity. Since 
knocking down APP significantly reduced ER stress as well as autophagic-lysosomal 
burden (Figure 17), there could be other pathways or mechanisms via which APP 
affects these processes. 
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Figure 22: Mechanistic implications of γ-secretase inhibiton on senescence 
markers in neuroblastoma cell line. Immunoblot analysis indicating the effect of γ-
secretase inhibition on markers of senescence and proteotoxicity, which were 
influenced by the overexpression of APP in SH-SY5Y cell lines (n=3), β-actin was 
used as the loading control. 
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DISCUSSION 
Proteostasis is an essential mechanism in a cell, necessary to keep up with the 
continuous protein turnover throughout its development. Undesirable or excess 
proteins in a cell have an adverse effect on its homeostasis. Cells that experience 
stresses such as ROS, radiation, etc. thereby initiating DDR, could also incur the 
accompanied protein damage. Misfolded, unfolded or erroneous proteins could 
cause proteotoxicity. Hence, strict regulation of the proteostatic machinery is highly 
important159. 
Proteotoxicity has long been associated with neurodegenerative disorders. From a 
histological perspective, the misfolded and/or aggregated proteins are present in the 
affected areas of the brain and have thus been established as the pathological 
hallmarks of their respective neurodegenerative disorders. Moreover, genes that are 
associated with an increase in the instances of their respective protein aggregation 
have been linked to the familial forms of the neurodegenerative disease. 
Understanding the role of these genes and the impact of their mutations on the 
aggregation of the proteins improves our understanding of the disease pathology183. 
For e.g., missense mutations in APP engender accumulation of Aβ in AD. 
Transgenic mouse models that over express the disease associated mutant human 
genes result in the aggregation of their associated proteins. This results in some of 
the clinical and pathological symptoms of the disease184. 
On the other hand, our lab has recently established that there is proteotoxic stress 
coupled with SASP, which leads to senescence-associated metabolic 
reprogramming. SASP factors disrupt the protein homeostasis in a cell due to an 
increase in production of cytokines and chemokines. Senescent cells have increased 
senescence related oxidative stresses that elevates the formation of misfolded 
proteins. This leads to ER stress, UPR and autophagic-lysosomal burden, correlated 
with senescent cells70. 
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 1 Therapy-induced cancer cell senescence, SASP and Alzheimer 
Disease 
Identification of genes that are involved in AD has been complicated. Genome-Wide 
Association Studies (GWAS) and next-generation sequencing (NGS) studies have 
unveiled that a lot of genes that appear to be involved in AD are also linked to 
several other pathways, such as lipid metabolism, immune response, and 
endocytosis/synaptic function185. Some of these genes have been curated and 
presented in the KEGG pathway for AD. A subset of these genes appeared to be 
altered in TIS control;bcl2 lymphomas. But on the other hand, in other types of 
senescence such as OIS of MEFs, the up regulation of the AD machinery was not 
observed. It could be due to different mechanisms behind OIS in MEFs and TIS in 
murine control lymphomas186. Therefore, in this thesis, we discuss the crosstalk 
between therapy-induced cancer cell senescence and AD. 
We observed that in control;bcl2 lymphomas, TIS affected the expression levels of 
AD genes. However, in senescence incapable Suv39h1-/-;bcl2 lymphomas these 
genes were minimally altered after ADR therapy. This data showed that the AD 
machinery is significantly more pronounced in TIS. Moreover, the alteration of the 
AD machinery was not recapitulated when senescence was induced independent of 
a SASP response. SASP and SASP related proteotoxic stress is complimentary with 
ADR induced TIS but not with rapamycin-induced senescence70 (Figure 23). This 
suggests that although the role of AD machinery is correlated with TIS in control;bcl2 
lymphomas, it is only observed when SASP is also present. Likewise, suppression of 
SASP by NF-κB-inactivation resulted in lower expression levels of the AD 
machinery. This reinforced our rationale that the AD machinery is correlated to TIS, 
via SASP. 
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Figure 23: Rapamycin-induced senescence, SASP and proteotoxicity. Dörr et al 
depicted that ADR induced TIS but not rapamycin induced TIS of control;bcl2 
lymphomas presents with SASP and its related proteotoxic stress. (A) RQ-PCR 
demonstrated the difference in the gene expression levels of SASP factors in 
rapamycin treated/untreated lymphomas as compared to ADR treated/untreated. (B) 
They further demonstrated that rapamycin-induced senescence does not 
accompany energy-demanding proteotoxicity-driven ER stress, although the 
autophagic machinery is elevated. This was shown by immunoblot analysis of 
AMPK-P-T172, AMPK, ATF4, p62/SQSTM1, V-ATPase A1 and MAP1-LC3-I/II of 
untreated vs. rapamycin induced TIS control;bcl2 lymphomas. 
Additionally, Sheng and colleagues observed that LPS induced neuroinflammation in 
the brain of APP transgenic mice upregulated APP as well as its cleavage via the 
amyloidogenic pathway187. However, in control;bcl2 lymphomas, LPS induced 
inflammatory response did not affect the expression of the two major AD genes- 
APP and Psen1. This confirmed that in control;bcl2 lymphomas both TIS and its 
associated inflammatory response (SASP) are essential for the induction of the AD 
machinery.  
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 2 APP and Psen1 may contribute to AD via senescence 
It is widely known that senescence is a concurrent companion of age-related 
pathologies132. Accumulation of senescent cells in the affected tissues is associated 
with the onset of the disease. In an AD inflicted brain, cells such as astrocytes and 
microglia display features of senescence188. Corresponding to this, we found that 
particularly in the brain of older APPPS1+/- transgenic mice, senescent cells were 
present in abundance. This implies that when genes related to AD are altered in 
these transgenic mice, it not only results in the development of Aβ plaques but also 
causes more brain cells to senesce. By directly correlating the SA-β-gal positive cells 
with the Aβ plaques, we realized the simultaneous presence of senescent cells and 
features of AD in these mice. 
From a senescence view point, we observed an upregulation of APP and other AD 
genes in TIS control;bcl2 lymphomas. Similarly, when TIS was induced in 
control;bcl2 lymph node bearing mice by CTX treatment, the associated AD genes 
should be upregulated. Therefore, in line with the transgenic APPPS1+/- mouse 
model, where we postulate that senescence precedes the formation of Aβ plaques, 
we analyzed the lymph node sections comprising of control;bcl2 lymphomas. We 
observed for the presence of plaques in TIS control;bcl2 lymph nodes. We were 
unable to detect Aβ plaques in the TIS lymph nodes sections. It could be because 
formation of plaques might be a brain specific phenotype. Alternatively, one could 
postulate that even if Aβ was expelled from the lymphoma cells, the flow through of 
fluids via the lymph nodes could wash away the secreted or exocytosed products. 
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 3 Senescence related stress on autophagic-lysosomal machinery 
can potentially contribute to AD pathology 
The link between a faulty lysosomal network and the mechanism involved in 
neurodegeneration is well studied189–192. A neuron is a differentiated cell that is 
unable to dilute the toxic protein buildup by cell division. Therefore, the efficiency of 
the lysosomal machinery is fundamental for their survival. The inability to achieve 
this results in the accumulation of aggregated proteins and peptide fragments, which 
induce toxicity in the cell193. Certain autophagy-related genes along with defective 
autophagic-lysosomal machinery have also been correlated with neurodegenerative 
diseases. The risk factors driving the formation of Aβ peptides and other AD 
pathology also influence the lysosomal network. Amelioration of the lysosomal 
network dysfunction has been observed to have therapeutic effects on the 
pathological and cognitive deficits in animal models of AD. This proves that 
malfunctioning of the autophagic-lysosomal machinery contributes significantly to the 
pathology of AD and other neurodegenerative disorders194.  
In the brains of APPPS1+/- transgenic mice, we found that the senescent cells 
appeared in young AD mice before the plaques were formed. Furthermore, Huang 
Yu and colleagues also demonstrated that autophagic vacuoles (AV) appear in 
neurons of these mice at a younger age, before Aβ plaques are formed93. This 
suggests that these gene mutations initially induce senescence as well as 
proteotoxicity, which are also correlated with each other. Moreover, this leads to a 
burden on the autophagic-lysosomal machinery, which could contribute towards 
some of the pathological features of an AD brain, such as plaque formation. 
Therefore, we postulate that these mutations of AD results in a compromised 
autophagic-lysosomal machinery via senescence and proteotoxicity. 
Moreover, in transgenic mouse models of AD, specifically involving APP mutations, 
there is an accumulation of autophagy substrates like MAP1-LC3-II as well as p62 in 
the AV175. The inability to eliminate the autophagy substrates affects the clearance of 
many AD related proteins, such as Aβ, tau and other factors promoting cell death195. 
APP substrates and secretases are present in abundance in the AVs, where the Aβ 
peptides are generated during autophagy93. Under normal conditions, these peptides 
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are degraded by the lysosomes196–198. But in case of a compromised autophagic-
lysosomal system, there is an accumulation of AVs in the cells. The Aβ produced in 
the endosomes is transferred to the lysosomes directly or during autophagy. These 
Aβ containing lysosomal compartments could be the reservoirs of Aβ 
immunoreactivity in AD brain93,199. In consensus of this, we observed that over 
expression of the Swedish mutation of APP, in a neuroblastoma cell line, led to an 
increased burden on the proteosomal and autophagic machinery, as well as the 
markers of senescence. APP is central to the formation of plaques. Therefore, this 
suggests the possibility that both these processes, induced by APP, collectively 
contribute to the AD pathology. 
The other AD related gene, PSEN, is also known to be involved in the proteolytic 
machinery of a cell. It is necessary for the proper functioning of the autophagic-
lysosomal system200. In cases where PSEN1 mutations contribute to AD, a 
disruption in the lysosomal proteolysis as well as autophagy is observed92. 
Therefore, it can be postulated that in the transgenic AD mouse models, PSEN 
mutation also contributes towards the disruption of proteostasis, leading to 
proteotoxicity, which precedes Aβ plaque formation in an AD inflicted brain93. Since 
all these features also overlap with features of a senescent cell, one can hypothesize 
that these genes could also be involved in senescence. 
  
DISCUSSION 
 97 
 4 APP overexpression by itself does not induce TIS in a 
neuroblastoma cell line 
Apart from the control lymphomas, TIS is also relevant with respect to some cancer 
cell lines. In case of neuroblastoma, we observed that APP overexpression in SH-
SY5Y cell line led to the up regulation of the markers of senescence, including 
markers of autophagic-lysosomal burden and ER stress, suggesting an induction of 
a pre-existing senescence burden. This also indicated a mechanistic correlation 
between APP and senescence. Although the proteotoxicity burden could be the 
reason for the slower growth rate of APP overexpressing SH-SY5Y cells compared 
to the parental cells, it was not enough to induce senescence. This could be due to 
the robustness of the immortal cell line. Moreover, despite the pre-existing 
senescence burden by APP in the SH-SY5Y cell line, there was no influence on its 
response to ADR induced TIS, as compared to the parental cell line. 
Additionally, both the parental as well as the APP overexpressing neuroblastoma cell 
lines displayed many features of senescence; but only a subpopulation of the cells 
were senescent after ADR treatment. This could be due to the possibility that there 
are some other factors involved, which prevented the remaining cells from 
undergoing senescence, such as suboptimal levels of ADR dosage. Further work in 
additional cell lines, as an alternative model system, would be required to confirm 
the association between APP overexpression and TIS. 
 5 APP contributes to senescence associated ER stress 
It has been well studied that APP, PSEN1, and their mutations contribute towards 
proteotoxicity in a cell in many different ways92,175,200. It could be either by over 
burdening of the proteosomal system or incapacitating the autophagic machinery or 
both. These systems are extremely important for maintaining autophagy balance in a 
senescent cell70. An imbalance in these systems could result in disturbing the 
senescent state of the cell. When we induced TIS in APP, and PSEN1 knockdown 
control;bcl2 lymphomas, there was no difference in their senescing ability as 
compared to the controls. This suggested that although there is an overlap between 
features of senescence and AD related genes in a cell, they are a part of a 
complicated biological process. It is possible that the impact of these players is one 
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of the many regulatory factors involved in senescence. Therefore, just altering these 
genes did not culminate into a significant effect on senescence. 
Looking closely, knocking down APP expression by shAPP-transduction also led to 
the reduction of its protein levels. However, post TIS its expression was restored as 
in the TIS control-transduced lymphomas. This implies that the protein expression of 
APP in lymphomas is closely regulated and over a certain limit the APP protein is 
possibly degraded. Furthermore, the opposite impact of reduced APP expression on 
p21 and H3K9me3 expression in ADR untreated cells does not explain its definitive 
mechanism in senescence. But knocking down APP expression significantly led to 
the mitigation of ER stress that was not restored post-TIS. This suggests that APP 
does contribute to ER stress associated with TIS in lymphomas. Decreasing the APP 
levels also reduced the autophagic-lysosomal burden in untreated cells, observed by 
reduced MAP1-LC3-I-isoform to MAP1-LC3-II-isoform conversion, but it was also 
restored to the TIS level of the controls post TIS. vATPase A1 expression was also 
significantly decreased when APP expression was reduced, suggesting an impact of 
APP on autophagic flux and activation of the lysosomal vacuolar type H+-ATPase. 
But since the autophagy is restored to the control state post-TIS, the expression of 
vATPase A1 is also restored. 
 6 Inhibition of APP processing using a Gamma-secretase inhibitor  
γ–secretase is a lucrative target for AD. Its inhibition causes interception in the 
formation of Aβ, the key culprit of the disease201. Theoretically, inhibiting this enzyme 
should alleviate the influence of Aβ towards the autophagic and proteotoxic stress 
caused by the accumulation of these peptides202–206. We used SH-SY5Y cell line 
overexpressing APP to determine the effects of γ–secretase inhibition and to 
understand the probable link between senescence and APP. These cells were 
chosen because they are commonly used as a model system to study AD207. 
Moreover, an APP overexpression helped in better visualization of the substrate 
since endogenous levels of APP are difficult to observe by many routine techniques, 
as was also observed by Sheng et. al.187. Hence, overexpression of APP is a useful 
tool for understanding the APP biology.  
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Semagacestat is one of the many γ–secretase inhibitors available and is well 
documented for blocking the generation of Aβ. It was selected for the γ–secretase 
Alzheimer Trial. However, at phase II of the trials, there was no significant impact 
reported on the levels of Aβ in the cerebrospinal fluid (CSF) of humans208. This could 
be a probable reason for their failure at the advance stages of the trial209. 
Interestingly, after γ–secretase inhibition in control lymphomas, we observed a 
decrease in the viability of senescent cells, which was not observed when solely the 
vehicle was administered. Moreover, γ–secretase inhibition did not appear to have 
any impact on the viability of the non-senescent cells. This suggests that γ–
secretase inhibition can lead to the selective killing of senescent cells. 
Mechanistically, γ–secretase inhibition blocks the final cleavage of the c-terminal 
fragment of APP and renders it membrane bound99. Since Aβ is not produced, we 
were interested in studying its impact on proteotoxicity as well as other markers of 
senescence. Reduction in Aβ production, in theory, should reduce proteotoxic stress 
in the cell due to its proteotoxic effects. APP is processed via a combination of 
enzymes including γ–secretase, and Aβ is considered pathologically relevant for AD. 
We could validate that inhibition of APP processing by Semagacestat resulted in the 
accumulation of C99 and C83 fragments in SH-SY5Y cell line overexpressing APP, 
thus confirming the blockage of Aβ production. Immunoblot analysis confirmed the 
size of the accumulated peptide, whereas immunofluorescence confirmed increase 
in signal pertaining to cumulative APP and its membrane bound C-terminal 
fragments. However, this did not convincingly reduce the expression of senescence 
or the proteotoxicity markers induced by overexpressing APP. This suggests that 
although APP contributes towards the senescence and the proteotoxic features in a 
cell, inhibiting γ–secretase to impede Aβ production is not enough to rescue the cells 
from these effects. It is also possible that Aβ is a contributing factor towards these 
phenotypes but it is not the exclusive factor. There could be other APP processing 
products or their downstream effectors involved that may have the same or greater 
effect on these phenotypes. 
In control lymphomas undergoing TIS, the γ–secretase inhibition did not result in an 
accumulation of the C-terminal fragment, as observed by immunoblot analysis. 
Nonetheless, some increase in signal was observed by immunofluorescence. This 
DISCUSSION 
 100 
could be due to the previous reports and observations that endogenous expression 
levels of APP might be lower than the detection threshold of immunoblot analysis. 
But since senescence leads to an upregulation of APP levels, blocking APP 
processing resulted in further accumulation of APP and its fragments. Furthermore, 
senescent cells have a stressed proteosomal as well as autophagic-lysosomal 
machinery, and inhibiting γ–secretase might add onto the backlog for clearance via 
the aforementioned mechanisms. Additionally, similar to our observation in 
neuroblastoma cell lines, expression of senescence and proteotoxicity markers 
remained unchanged post γ–secretase inhibition in UT as well as TIS control;bcl2 
lymphomas.  
Knocking down of APP in control;bcl2 lymphomas resulted in a reduction in 
senescence associated ER stress, whereas inhibiting Aβ production via γ–secretase 
did not alleviate the ER stress. Therefore, we conclude that APP induces ER stress 
through an Aβ-independent mechanism. 
Interestingly, another study suggested that before the Aβ plaques appear in triple-
transgenic mice (3xTgAD) overexpressing Swedish-mutated amyloid precursor 
protein, P310L-Tau (TauP301L), and physiological levels of M146V-presenilin-1 
(PS1M146V), it demonstrates C99 accumulation. This is considered to be an initiator of 
the neurodegenerative process and cognitive alterations in this model system210. 
They demonstrated that C99 accumulated due to an impaired autophagic-lysosomal 
machinery rather than a deteriorated γ–secretase processing. They also established 
that an impaired autophagic-lysosomal machinery results in the accumulation of 
C99, which further contributes to the dysfunction of this machinery211. This could 
also be a plausible alternative explanation of the senolytic behavior of the γ–
secretase inhibitor that was observed in control lymphomas. Although the expression 
levels of these players were below the detection thresholds, it can be postulated that 
the accumulation of C99 after γ–secretase inhibition could induce excess pressure 
on the carefully balanced autophagic-lysosomal machinery, causing the cells to 
succumb to proteotoxicity. 
Most of the studies of APP and other components of AD are performed in neuronal 
systems. Even though APP is a ubiquitous protein, their expression level varies from 
one cell type to the other. The APP protein and mRNA expression has been 
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observed in the brain, thymus, heart, muscle, lung, kidney, adipose tissue, liver, 
spleen, skin, and intestine212–219. This implies that although the relevance of APP is 
more pronounced in the context of AD, its wide-spread expression suggests that it 
has alternative functions as well220. 
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 7 Conclusion 
The existence of common underlying biology behind various pathologies and 
diseases can be used to an advantage. Knowledge and understanding from one 
disease can be incorporated for improving the prognosis of another. The senescent 
cells can be a threat to an organism as they possess the ability to modify their tissue 
environment, for better or for worse221. Albeit senescence has been, for the longest 
time, associated with ageing and cancer, there is more work being done that has 
shown its relevance in many other physiological and pathophysiological processes. 
Senescent cells have been identified during embryogenesis as well as in 
neurodegenerative diseases like AD9,222. Clearance of these senescent cells or their 
modification have, in the past, delayed the onset of such senescence related 
pathologies221,223. Therefore, targeting this mechanism can contribute towards 
prolonging health during aging. 
Up regulation of the AD genes in Eμ-myc-driven B-cell lymphomas was observed 
only when TIS presented with SASP. Key components of the AD machinery, APP 
and PSEN1 are associated with the most common forms of FAD. There have also 
been evidences suggesting their direct or indirect contribution towards proteotoxicity 
associated with its pathology92,200,224. The influence of some selected AD players on 
proteotoxicity associated with TIS control lymphomas were investigated with the aim 
to discover new drug target sites to specifically eliminate senescent cells. Drugs 
targeting these sites could contribute towards the development of senolytic drugs.  
Knock down of APP did not have a direct impact on the ability of the cells to undergo 
senescence. Therefore, these major AD players did not impact senescent cells as 
we hypothesized. However, knocking down of APP led to the reduction of 
senescence-associated ER stress. In conclusion, although these AD players have 
been shown to contribute, directly or indirectly, towards proteotoxicity as well as 
senescence, but they are components of a larger regulatory network involving 
additional players. Moreover, inhibiting APP processing with γ–secretase inhibition 
did not strongly alleviate the proteotoxic stress associated with senescence in 
neither neuroblastoma cell line nor control lymphomas. This could either mean there 
are other factors apart from Aβ that also contribute to the features under review or 
the resulting accumulation of the C99 fragments substitute for the effects of Aβ. 
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The primary focus of this thesis has been to explore the link between senescence 
and AD. According to which we could show that APP contributes towards 
senescence-associated proteotoxic stress, but in an Aβ-independent manner. 
 8 Future directions 
Although we could identify that proteotoxicity and SASP is a link between therapy-
induced cancer cell senescence and AD, we could not deduce the specific role of the 
AD genes in senescence. We concentrated our study on APP because it is widely 
known to be involved in genetic forms of AD, but the functions of APP are not well 
understood. Therefore, further work is required to understand its role, especially in 
the context senescence. 
 8.1 Can overexpression of APP in lymphomas lead to 
senescence? 
As we observed in the neuroblastoma cell lines, overexpressing APP led to an 
upregulation of many senescence markers, generating a senescence burden. But 
this was not sufficient to induce senescence in an immortal cell line. Therefore, it will 
be interesting to see if overexpressing APP in primary cells such as control;bcl2 
lymphomas would be able to induce a similar senescence burden, and potentially 
induce senescence. This would confirm APP as a component of the senescence 
pathway, since in this system we observed its upregulation in TIS. 
Alternatively, overexpression of wildtype APP, in some cellular systems, has been 
shown to induce apoptosis225. In other studies, mutations of APP causes ER stress- 
induced apoptosis204. This further suggests that inducing apoptosis via APP in cells 
overexpressing the anti-apototic gene Bcl2 could induce senescence by avoiding 
apoptosis. 
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 8.2 Elucidating the mechanism behind the senolytic effects of 
gamma–secretase inhibition 
We observed that knocking down of APP in control;bcl2 lymphomas resulted in a 
mitigated ER stress even after TIS. This hints towards significant contribution of APP 
in causing TIS associated ER stress. Different APP-related studies suggest 
contrasting root causes of ER stress which could be Aβ-dependent, Aβ-independent, 
etc204,225,226. But in case of control;bcl2 lymphomas, we observed that restricting the 
production of Aβ by γ–secretase inhibition did not affect ER stress, suggesting that 
ER stress was induced in an Aβ-independent fashion. Since γ–secretase is also 
involved in the notch signaling pathway, it is necessary to determine the impact of 
notch signaling in this context136.  
Therefore, it is possible that the senolytic effects of Semagacestat could be due to 
C99 accumulation211 or via notch pathway, which needs to be further investigated. 
Hypothetically, if Semagacestat exhibits senolytic potential via notch pathway, γ–
secretase modulators can be used. γ–secretase modulators modulate γ–secretase 
activity instead of completely inhibiting it227. Therefore, by more specifically targeting 
APP and its processing, we can further understand its role and implications in the 
senescence. 
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